

CURRICULUM VITAE

Name

David S. Ettinger

Appointments

University:

Alex Grass Professor of Oncology
The Johns Hopkins University
School of Medicine

Professor of Medicine
The Johns Hopkins University
School of Medicine

Professor of Otolaryngology-
Head and Neck Surgery
The Johns Hopkins University
School of Medicine

Professor of Gynecology and
Obstetrics
The Johns Hopkins University
School of Medicine

Professor of Radiation Oncology
and Molecular Radiation Sciences
The Johns Hopkins University
School of Medicine

Hospital:

Active Staff in Oncology
The Johns Hopkins Hospital

Active Staff in Medicine
The Johns Hopkins Hospital

Active Staff in Otolaryngology-
Head and Neck Surgery
The Johns Hopkins Hospital

Active Staff in Gynecology
and Obstetrics
The Johns Hopkins Hospital

Addresses

Office: The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
Bunting Blaustein Cancer Research Bldg.
1650 Orleans Street, Rm. G88
Baltimore, Maryland 21231-1000
Tel. (410) 955-8847

Home: 2511 Lawnside Road
Timonium, Maryland 21093
Tel. (410) 252-5722

Personal and Family

Date of Birth: March 16, 1942
Place of Birth: Brooklyn, New York
Marital Status: Married
Wife's Name: Phyllis
Year of Marriage: 1964
Children: Laura Year: 1968
Daniel 1969
Kathryn 1972

Educational, Military, and Academic Experience

1959-63 B.A., Yeshiva University
New York, New York

1963-67 M.D., University of Louisville School of
Medicine, Louisville, Kentucky

1964 Muscular Distrophy Association (Summer
Fellowship), Montefiore Hospital
Bronx, New York

1965 New York University, Institute of Physical
Medicine and Rehabilitation (Summer
Fellowship), St. Vincent's Hospital, New
York, New York

1966 Kentucky Arthritis Association (Summer
Fellowship), Louisville, Kentucky

- 1967-68 Intern, Rotating 1, Albany Medical Center Hospital, Albany, New York
- 1968-71 Fellow, Internal Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota
- 1971-72 Assistant Chief, Department of Medicine
U.S. Army, U.S. Munson Army Hospital
Fort Leavenworth, Kansas
- 1972-73 Chief, Department of Medicine, U.S. Army, U.S. Munson Army Hospital, Fort Leavenworth, Kansas
- 1973-75 Fellow, Department of Medicine, Section of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1975-76 Instructor in Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1975-77 Instructor in Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1975- Active Staff in Medicine, The Johns Hopkins Hospital, Baltimore, Maryland
- 1976-81 Assistant Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1977- Active Staff in Oncology, The Johns Hopkins Hospital, Baltimore, Maryland
- 1977-81 Assistant Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1981-92 Associate Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland

- 1981-93 Associate Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1983-2002 Associate Professor of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1983- Part Time Staff in Gynecology and Obstetrics, The Johns Hopkins Hospital, Baltimore, Maryland
- 1986-2001 Associate Professor of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1986- Active Staff in Otolaryngology - Head and Neck Surgery, The Johns Hopkins Hospital, Baltimore, Maryland
- 1992- Professor of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 1993- Professor of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 2001- Professor of Otolaryngology - Head and Neck Surgery, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 2002- Professor of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 2003- 1st Recipient: Alex Grass Professorship in Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland
- 2003- Professor of Radiation Oncology and Molecular Radiation Sciences The Johns Hopkins University School of Medicine, Baltimore, Maryland

Certifications

1968	Licensed to Practice Medicine State of Kentucky
1968	Licensed to Practice Medicine State of Minnesota
1972	Licensed to Practice Medicine State of Kansas
1973	Licensed to Practice Medicine State of Missouri
1974	Licensed to Practice Medicine State of Maryland
1976	Diplomate, Internal Medicine American Board of Internal Medicine
1977	Diplomate, Sub-Specialty of Medical Oncology, American Board of Internal Medicine

Honors

1986-89	Professor of Clinical Oncology American Cancer Society Maryland Division
1997	National Divisional Award, St. George Medal American Cancer Society

Membership in Professional Societies

1964-	Phi Delta Epsilon Medical Fraternity
1967-71	Mayo Clinic Fellows' Association (Treasurer, 1970-71)
1968-73	Minnesota Medical Association
1968-75	American Medical Association

1969-73	Associate, The American College of Physicians
1973-	Mayo Clinic Alumni Association
1973-	Yeshiva University, New York Zeta Chapter Alpha Epsilon Delta-Premedical Honor Society
1975-	Eastern Cooperative Oncology Group
1977-	American Society of Clinical Oncology
1977-	International Association for the Study of Lung Cancer
1978-	American Association for Cancer Research
1978-80	Member, American College of Physicians
1980-	Fellow, American College of Physicians
1989-	American Association for the Advancement of Science
1992-	Member, Multinational Association of Supportive Care in Cancer
1999-	Member, Connective Tissue Oncology Society
2003-	Member, American Society for Therapeutic Radiology and Oncology
2005-	Member, American College of Chest Physicians
2005-	Fellow, American College of Chest Physicians

Consultant Appointments

1975-78	Member, Board of Directors, American Cancer Society, Baltimore City Unit
1976-95	Study Chairman, Lung Committee, Eastern Cooperative Oncology Group

- 1976-78 Chairman, Patient Assistance Committee, American Cancer Society, Baltimore City Unit
- 1977-1997 Member, Service and Rehabilitation Committee, American Cancer Society, Maryland Division
- 1978-80 President, East Baltimore Community Unit, American Cancer Society
- 1978-92 Member, Steering Committee, New Agents and Pilot Studies Committee, Eastern Cooperative Oncology Group
- 1978-80 Co-Chairman, Lung Committee, Eastern Cooperative Oncology Group
- 1979-80 Member, House of Delegates and Board of Directors, American Cancer Society, Maryland Division
- 1979-84, 1993- Co-Principal Investigator, Eastern Cooperative Oncology Group
- 1979 Consultant, Special Study Section Division of Research Grants, National Institutes of Health
- 1980- Member, Medical Oncology Committee Radiation Therapy Oncology Group (RTOG)
- 1980-82 Chairman, Lung Committee, Eastern Cooperative Oncology Group
- 1982-84 Member, Board of Directors, American Cancer Society, Towson Unit
- 1982-90 Principal Investigator, Phase I Studies of New Anticancer Agents, National Cancer Institute
- 1983-86, 1990-92 Chairman, Service and Rehabilitation Committee, American Cancer Society, Maryland Division
- 1983-97 Member, Board of Directors, American Cancer Society, Maryland Division

1983-86, 1990-97	Member, Executive Committee, American Cancer Society, Maryland Division
1984-93	Principal Investigator, Eastern Cooperative Oncology Group
1984-86, 1993-95	Member, Executive Committee, Eastern Cooperative Oncology Group
1984-86	Co-Chairman, New Agents and Pilot Studies Committee, Eastern Cooperative Oncology Group
1985, 1989	Consultant, Division of Drugs and Toxicology, American Medical Association
1986-88	Member, Field Services Committee, American Cancer Society, Maryland Division
1986-88	Member, Nominating Committee, Eastern Cooperative Oncology Group
1987-92	Chairman, New Agents and Pilot Studies Committee, Eastern Cooperative Oncology Group
1990-97	Member, Planning Advisory Council, American Cancer Society, Maryland Division
1990-	Chairman, Medical Oncology Lung Subcommittee, Radiation Therapy Oncology Group
1990-95	Co-Principal Investigator, Phase I Studies of New Anticancer Agents, National Cancer Institute
1991-92	Member, Program Committee, American Society of Clinical Oncology
1992-96	Member, Pharmacology Committee, Eastern Cooperative Oncology Group

1992-94	Vice President, American Cancer Society, Maryland Division
1992-96	Member, Finance Committee, American Cancer Society, Maryland Division
1992-	Clinical Director, SPORE grant, Lung Cancer, National Cancer Institute
1993	Consultant, NCI-Sponsored Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Trial in Finland
1994-96	President, American Cancer Society, Maryland Division
1994-95	Member, Research Education Foundation, Eastern Cooperative Oncology Group
1994-	Member, Maryland Society of Clinical Oncology
1994-	Member, Adult Guidelines Steering Committee, National Comprehensive Cancer Network (NCCN)
1995-	Chairman, Off Label Use of Drugs Panel, State of Maryland
1995-96	Member, Special Awards Committee, American Society of Clinical Oncology
1995-	Panel Chairman, Non-Small Cell Lung Cancer Guidelines, National Comprehensive Cancer Network (NCCN)
1996	Member, Conference Planning Committee, National Comprehensive Cancer Network (NCCN)
1996-	Panel Chairman, Antiemetic Guidelines, National Comprehensive Cancer Network (NCCN)
1997-1998	Panel Chairman, Occult Primary Guidelines, National Comprehensive Cancer Network (NCCN)

1998-2000	Panel Chairman, Neuroendocrine Tumors Guidelines, National Comprehensive Cancer Network (NCCN)
1998-	Member, Board of Directors, National Comprehensive Cancer Network (NCCN)
1999-	Member, Medical Advisory Board, Best Doctors
2001-	Member, Clinical Trials Committee, Association of American Cancer Institutes
2002-	Member, Data Safety Monitoring Committee, Cell Therapeutics, Inc., Seattle, Washington
2003-	Consultant, Oncologic Drugs Advisory Committee (ODAC), Food and Drug Administration, Center for Drug Evaluation and Research
2004-	Member, Advisory Board, Office of Funded Programs/CME, The Johns Hopkins School of Medicine

Editorial Appointments

1988-90	Member, Editorial Board Journal of Clinical Oncology
1991-	Member, Editorial Board (North America) Journal of Cancer Research and Clinical Oncology
1992-2001	Member, Editorial Board Lung Cancer
1992-93	Section Editor Current Opinion in Oncology
1992-95	Member, Editorial Board Mayo Clinic Proceedings
1993-97	Member, Editorial Board Oncology: International Journal of Cancer Research and Treatment

- 1996- Section Editor, Oncology, Current Practice of Medicine, Roger C. Bone, Series Editor, Churchill Livingstone, Inc., New York, NY
- 1997- Member, Editorial Board
The Oncologist
- 1998- Associate Editor, Oncology
- 2000- Member, Editorial Board, Praxis MD
- 2003- Member, Editorial Advisory Board, Clinical Advances in Hematology and Oncology

Editorship

- 2000- Editor-in-Chief, Current Treatment Options in Oncology
- 2001- Editor, *THORACIC ONCOLOGY* in Cancer Treatment and Research Series, Kluwer Academic Publishers
- 2004- Issue Editor, JCCN, Volume 2
- 2004- Guest Editor, *ONCOLOGY*, Volume 8 (Suppl 4)

Academic Service

- 1978-83 Member, Physician Advisors Committee
The Johns Hopkins Hospital
- 1979-80 Member, Pharmacy Task Force
The Johns Hopkins Hospital
- 1979-80 Member, Staff Conference Committee
The Johns Hopkins Hospital
- 1982-84 Physician Administrator, The Experimental Therapeutics Unit, Johns Hopkins Oncology Center
- 1983 Chairman, Physician Advisors Committee, The Johns Hopkins Hospital

1983-85	Co-Chairman, Medical Care Evaluation Committee, The Johns Hopkins Hospital
1985-91	Chairman, Medical Care Evaluation Committee, The Johns Hopkins Hospital
1985-87	Member, Incident Review Committee, The Johns Hopkins Hospital
1985-89	Director, Community Programs, The Johns Hopkins Oncology Center
1988	Member, Medical Programs Group, Medical Director of Quality Assurance and Utilization Management, The Johns Hopkins Hospital
1988-	Member, Risk Management Committee, The Johns Hopkins Hospital
1989-	Director, Lung Cancer Program The Johns Hopkins Oncology Center
1991-98	Director, Outpatient Department The Johns Hopkins Oncology Center
1991-	Member, Credentials Committee, The Johns Hopkins Hospital
1992-95	Member, Admissions Committee, The Johns Hopkins University School of Medicine
1992-	Associate Director for Clinical Research, The Johns Hopkins Oncology Center
1992-98	Associate Director for Clinical Affairs, The Johns Hopkins Oncology Center
1992-	Member, Executive Committee, The Johns Hopkins Oncology Center
1992-99; 2002-	Member, Appointments and Promotions Committee, Johns Hopkins Oncology Center

1992-	Member, Fellowship Selection Committee The Johns Hopkins Oncology Center
1993-	Medical Director, The Johns Hopkins Home Care Group
1994-98	Member, Interdepartmental Risk Management Committee, The Johns Hopkins Hospital
1995-98	Vice-Chairman, Appointments and Promotions Committee, The Johns Hopkins Oncology Center
1995-	Faculty Advisor - Medical Students, The Johns Hopkins Oncology Center
1995-	Member, The Johns Hopkins Outpatient Center Advisory Council
1996-98	Co-Director, Cancer Committee, The Johns Hopkins Hospital
1997-	Member, Operations Oversight Committee, Clinical Practice Association, The Johns Hopkins University School of Medicine
1997-98	Member, Compliance Committee, Clinical Practice Association, The Johns Hopkins University School of Medicine
1997-	Member, Board of Trustees, Hackerman-Patz House
1997-	Member, Board of Trustees, Rockwell House
1999-	Chairman, Executive Clinical Research Committee, The Johns Hopkins Oncology Center
2000-2001	Member, Professorial Promotions Committee Subcommittee, The Johns Hopkins School of Medicine

Articles Published in Peer-Reviewed Professional Journals

1. Ettinger DS, Humphrey RL, and Skinner MD. Kaposi's Sarcoma Associated with Multiple Myeloma. *Johns Hopkins Med J* 137:88, 1975.

2. Baylin SB, Abeloff MD, Wieman, KC, Tomford JW, and Ettinger DS. Elevated Histaminase (Diamine Oxidase) Activity in Small Cell Carcinoma of the Lung. *New Engl J Med* 293:1286, 1975.
3. Abeloff MD, Ettinger DS, Baylin SB, and Hazra T. Management of Small Cell Carcinoma of the Lung: Therapy, Staging, and Biochemical Markers. *Cancer* 38:1394, 1976.
4. Prystowsky SD, Vogelstein B, Ettinger DS, Merz WG, Kaizer H, Sulica VI, and Zinkham W. Invasive Aspergillosis. *New Engl J Med* 295:655, 1976.
5. Ettinger DS, Parmley T, Owellen RJ, and Davis TE. Endodermal Sinus Tumor: Report of a Case with Remission Following Chemotherapy. *Obstet Gynecol* 49:53s, 1977.
6. Ettinger DS, and Slavin RE. Radiation Enteritis Complicating Non-Hodgkin's Lymphoma. *Southern Med J* 70:637, 1977.
7. Wilcox PM and Ettinger DS. Benign Breast Disease - Diagnosis and Treatment. *Primary Care* 4:739, 1977.
8. Abeloff MD and Ettinger DS. Treatment of Metastatic Breast Cancer with Adriamycin-Cytosan Induction Followed by Alternating Combination Chemotherapy. *Cancer Treat Rep* 61:1685, 1977.
9. Ettinger DS and Carter D. Gastric Carcinoma 16 Years After Gastric Lymphoma Irradiation. *Am J Gastroent* 68:485, 1977.
10. Ettinger DS, Harker WG, Gerry HW, Sanders RC, and Saral R. Hyperphosphatemia, Hypocalcemia and Transient Renal Failure. *J Am Med Assoc* 239:2472, 1978.
11. Ettinger DS, Karp JE, Abeloff MD, Burke PJ, and Braine HG. Intermittent High-Dose Cyclophosphamide Chemotherapy in Small Cell Carcinoma of the Lung. *Cancer Treat Rep* 62:413, 1978.
12. Ettinger DS, Baylin SB, Minaberry D, Abeloff MD, and Mellits ED. Response of Plasma Histaminase Activity to Heparin in Normal Subjects and Patients with Small Cell Carcinoma of the Lung. *J Nat Cancer Inst* 60:1239, 1978.
13. Baylin SB, Weisburger W, Eggleston JC, Beaven MA, Abeloff MD, and Ettinger DS. Variable Content of Histaminase, L-Dopa Decarboxylase and Calcitonin in Small Cell Carcinoma of the Lung. *New Engl J Med* 299:105, 1978.
14. Gehrke SW, Waalkes TP, Borek E, Swartz WF, Cole TF, Kuo KC, Abeloff MD, Ettinger DS, Rosenshein NB, and Young RC. Quantitative Gas-Liquid Chromatography of Neutral Sugars in Human Serum Glycoproteins. Fucose, Mannose, and Galactose as Predictors in Ovarian and Small Cell Lung Carcinoma. *Journal of Chromatography* 162:507, 1979.

15. Ettinger DS, Dragon LH, Klein JL, Sgagias M, and Order SE. Isotopic Immunoglobulin in an Integrated Multimodal Treatment Program for a Primary Liver Cancer: A Case Report *Cancer Treat Rep* 63:131, 1979.
16. Abeloff MD, Eggelston JC, Mendelsohn G, Ettinger DS, and Baylin SB. Changes in Morphologic and Biochemical Characteristics of Small Cell Carcinoma of the Lung - A Clinicopathologic Study. *Am J Med* 66:757, 1979.
17. Ettinger DS, Vitale P, and Trump DL. Important Clinical Pharmacologic Considerations in the Use of Methadone in Cancer Patients. *Cancer Treat Rep* 63:457, 1979.
18. Order SE, Rosenshein NB, Klein JL, Lichter AS, Ettinger DS, Dillon MB, and Leibel SA. New Methods Applied to the Analysis and Treatment of Ovarian Cancer. *Int J Rad Oncol Biol Phys* 5:861, 1979.
19. Abeloff MD, Ettinger DS, Khouri NF, and Lenhard RE, Jr. Intensive Induction Therapy for Small Cell Carcinoma of the Lung. *Cancer Treat Rep* 63:519, 1979.
20. Rosenshein NB, Grumbine FC, Woodruff JD, and Ettinger DS. Pregnancy Following Chemotherapy for an Ovarian Immature Embryonal Teratoma. *Gynecol Oncol* 8:234, 1979.
21. Vaughan WP, Wilcox PM, Alderson PO, Ettinger DS, and Abeloff MD. Hepatic Toxicity of Adjuvant Chemotherapy for Carcinoma of the Breast. *Med Ped Onc* 7:351, 1979.
22. Giangreco A, Ettinger DS, Dragon LH, Gupta PK, and Lenhard RE, Jr. Sputum Cytologic Diagnosis of Hodgkin's Disease Involving the Lung. *Arch Int Med* 140:910, 1980.
23. Ettinger DS, Rosenshein NB, Parmley TH, Mendelsohn G, and Baylin SB. Tumor Cell Origin of Histaminase Activities in Ascites Fluid from Patients with Ovarian Carcinoma. *Cancer* 45:2568, 1980.
24. Taxy JB, Ettinger DS, and Wharam MD. Primary Small Cell Carcinoma of the Skin. *Cancer* 46:2308, 1980.
25. Order SE, Klein JL, Ettinger DS, Alderson PO, Siegelman S, and Leichner P. Phase I-II Study of Radiolabeled Antibody Integrated in the Treatment of Primary Hepatic Malignancies. *Int J Rad Oncol Biol Phys* 6:703, 1980.
26. Waalkes TP, Abeloff MD, Woo KB, Ettinger DS, Rudden RW, and Aldenderfer P. Carcinoembryonic Antigen for Monitoring Patients with Small Cell Carcinoma of the Lung During Treatment. *Cancer Res* 40:4420, 1980.
27. Order SE, Klein JL, Ettinger D, Alderson PO, Siegelman S, and Leichner P. Use of Isotopic Immunoglobulin in Therapy. *Cancer Res* 40:3001, 1980.

28. Order SE, Leichner P, Ettinger DS, Klein JL, and Strand M. Tumor Localization of Radiolabeled Antibodies. *New Engl J Med* 303:1238 (correspondence), 1980.
29. Ettinger DS, Stanley KE, and Nystrom JS. Phase II Study of High-Dose Methotrexate in Patients with Non-Small Cell Carcinoma of the Lung: An Eastern Cooperative Oncology Group Study. *Cancer Treat Rep* 64:1017, 1980.
30. Trump DL, Ettinger DS, Feldman J, and Dragon LH. "Sarcoidosis" and Sarcoid-Like Lesions Following Cytotoxic and Radiation Therapy of Testis Cancer. *Arch Int Med* 141:37, 1981.
31. Trump DL, Ettinger DS, and Abeloff MD. Doxorubicin, Vincristine, and Cis-Diamminedichloroplatinum (II) Therapy in Patients with Advanced Breast Cancer. *Med Ped Onc* 9:1, 1981.
32. Paone JF, Abeloff MD, Ettinger DS, Arnold EA, and Baker RR. The Correlation of Estrogen and Progesterone Receptor Levels with Response to Chemotherapy for Advanced Breast Carcinoma. *Surg Gynecol Obstet* 152:70, 1981.
33. Woo KB, Waalkes TP, Abeloff MD, Ettinger DS, McNitt KL, and Gehrke CW. Multiple Biological Markers in the Monitoring of Treatment for Patients with Small Cell Carcinoma of the Lung: The Use of Serial Levels of Plasma CEA and Serum Carbohydrates. *Cancer* 48:1633, 1981.
34. Waalkes TP, Abeloff MD, Ettinger DS, Woo KB, Gehrke CW, and Mrochek JE. Multiple Biological Markers and Breast Carcinoma: A Preliminary Study in the Detection of Recurrent Disease after Primary Therapy. *J Surg Oncol* 18:9, 1981.
35. Diasio RB, Ettinger DS, and Satterwhite BE. Oral Levonantradol in the Treatment of Chemotherapy-Induced Emesis: Preliminary Observations. *J Clin Pharmacol* 21:815, 1981.
36. Leichner PK, Klein JL, Garrison JB, Jenkins RE, Nicoloff EL, Ettinger DS, and Order SE. Dosimetry of ¹³¹I-Labeled Antiferritin in Hepatoma: A Model for Radioimmunoglobulin Dosimetry. *Int J Rad Oncol Biol Phys* 7:323, 1981.
37. Abeloff MD, Ettinger DS, Order SE, Khouri N, Mellits ED, Dorschel NT, and Baumgartner R. Intensive Induction Chemotherapy in 54 Patients with Small Cell Carcinoma of the Lung. *Cancer Treat Rep* 65:639, 1981.
38. Order SE, Rosenshein N, Klein JL, Leibel S, Pino y Torres J, and Ettinger D. The Integration of New Therapies and Radiation in the Management of Ovarian Cancer. *Cancer Suppl* 48:590, 1981.

39. Shuman RD, Ettinger DS, Abeloff MD, Livengood SV, and Fortuin NJ. Comparative Analysis of Noninvasive Cardiac Parameters in the Detection and Evaluation of Adriamycin Cardiotoxicity. *Johns Hopkins Med J* 149:57, 1981.
40. Ettinger DS and Lagkos S. Phase III Study of CCNU, Cyclophosphamide, Adriamycin, Vincristine and VP-16 in Small Cell Carcinoma of the Lung. *Cancer* 49:1544, 1982.
41. Delaney WE, Nikoloff E, Ettinger DS, Drew HM, Szeluga DJ, and Stuart RK. Abnormal Fatty Acid Breath Tests in Cancer Patients with Nutritional Correlation. *Cancer* 50:727, 1982.
42. Ettinger DS, Order SE, Wharam MD, Parker MK, Klein JL, and Leichner PK. Phase I-II Study of Isotopic Immunoglobulin Therapy for Primary Liver Cancer. *Cancer Treat Rep* 66:289, 1982.
43. Creech RH, Stanley K, Vogl SE, Ettinger DS, Bonomi PD, and Salazar O. Phase II Study of Cisplatin, Maytansine, and Chlorozotocin in Small Cell Lung Carcinoma (EST 2578) *Cancer Treat Rep* 66:1417, 1982.
44. Waalkes TP, Abeloff MD, Ettinger DS, Woo KB, Gehrke CW, Kuo KC, and Borek E. Biological Markers and Small Cell Carcinoma of the Lung. A Clinical Evaluation of Urinary Ribonucleosides. *Cancer* 50:2457, 1982.
45. Delaney WE, Stuart RK, and Ettinger DS. Fatty Acid Breath Test Values in the Malabsorption Range in Cancer Patients. *Nutr Cancer* 3:122, 1982.
46. Waalkes TP, Abeloff MD, Ettinger DS, Mrochek JE, and Bostick WD. Biological Markers as an Aid in the Clinical Management of Patients with Liver Metastases. *J Surg Oncol* 20:83, 1982.
47. Fetting JH, Grochow LB, Folstein MF, Ettinger DS, and Colvin M. The Course of Nausea and Vomiting after High-Dose Cyclophosphamide. *Cancer Treat Rep* 66:1487, 1982.
48. Hernandez E, Rosenshein NB, Pino y Torres J, Villar J, Grumbine FC, Ettinger DS, Dillon MB, Klein JL, and Order SE. Intraperitoneal Immunotherapy and Chemotherapy in Advanced Epithelial Ovarian Cancer. *Cancer Treat Rep* 66:1981, 1982.
49. Ettinger DS. Editorial Comment on Urological Presentations of Non- Hodgkin's Lymphoma. *J Urol* 128:956, 1982.
50. Waalkes TP, Rosenshein NB, Shaper JH, Ettinger DS, Woo KB, Paone JF, and Gehrke CW. A Feasibility Study in the Development of Biological Markers for Ovarian Cancer. *J Surg Oncol* 20:207, 1982.

51. Waalkes TP, Abeloff MD, Ettinger DS, Woo KB, Gehrke CW, Kuo KC, and Borek E. Modified Ribonucleosides as Biologic Markers for Patients with Small Cell Carcinoma of the Lung. *Eur J Cancer Clin Oncol* 18:1267, 1982.
52. Order SE, Klein JL, Leichner PK, Wharam MD, Ettinger DS, Siegelman SS. Advances in I¹³¹ Labeled Antiferritin Immunoglobulin Cancer Therapy. *The Cancer Bulletin* 34:264, 1982.
53. Pino JL, Bross DS, Hernandez E, Rosenshein N, Klein JL, Ettinger DS, Leichner PK, and Order SE. Multimodality Treatment of Advanced Ovarian Carcinoma. *Int J Rad Oncol Biol Phys* 8:1671, 1982.
54. Meek AG, Order SE, Abeloff MD, Ettinger DS, Baker RR, and Baral E. Concurrent Radio-Chemotherapy in Advanced Breast Cancer. *Cancer* 57:1001, 1983.
55. Hernandez E, Rosenshein NB, Villar J, Dillon MB, Ettinger DS, and Order SE. Alternating Multiagent Chemotherapy for Advanced Ovarian Cancer. *J Surg Oncol* 22:87, 1983.
56. Osterlind K, Ihde DC, Ettinger DS, Gralla RJ, Karrer K, Maurer HL, Sorenson S, Vincent R, Krause S, and Rorth M. Staging and Prognostic Factors of Small Cell Carcinoma of the Lung. *Cancer Treat Rep* 67:3, 1983.
57. Ettinger DS, Day R, Ferraro JA, Ruckdeschel JC, Woll JE, Creech RH, and Vogl SE. A Randomized Phase II Study of m-AMSA (NSC 249992) and Neocarzinostatin (NSC 157365) in Non-Small Cell Bronchogenic Carcinoma: An Eastern Oncology Cooperative Group Study. *Amer J Clin Oncol* 2:167, 1983.
58. Berkman AW, Woog JJ, Kickler TS, and Ettinger DS. Serial Determinations of Antiplatelet Antibodies in a Patient with Hodgkin's Disease and Autoimmune Thrombocytopenia. *Cancer* 51:2057, 1983.
59. Waalkes TP, Abeloff MD, Ettinger DS, Woo KB, Gehrke CW, and Kuo KC. Serum Protein-Bound Carbohydrates and Small Cell Carcinoma of the Lung. *Cancer* 52:131, 1983.
60. Leichner PK, Klein JL, Siegelman SS, Ettinger DS, and Order SE. Dosimetry of ¹³¹I-Labeled Antiferritin in Hepatoma; Specific Activities in the Tumor and Liver. *Cancer Treat Rep* 67:647, 1983.
61. Ettinger DS. Therapeutic Strategies in Non-Small Cell Lung Cancer. *Current Concepts in Oncology* 5:7, 1983.
62. Waalkes TP, Enterline JP, Shaper JH, Abeloff MD, and Ettinger DS. Biologic Markers for Breast Cancer. *Cancer* 53:644, 1984.

63. Ettinger DS, Tritchler D, Earhart R, and Creech RH. Phase II Study of PALA and PCNU in the Treatment of Non Small Cell Lung Cancer (EST 2580): An Eastern Cooperative Oncology Group Study. *Cancer Treat Rep* 68:1297, 1984.
64. Creech RH, Tritchler D, Ettinger DS, Ferraro JA, Ruckdeschel JC, Vogl SE, and Woll J. Phase II Study of PALA, mAMSA, VM-26, and Neocarzinostatin in Small Cell Lung Carcinoma (EST 2579). *Cancer Treat Rep* 68:1183, 1984.
65. Sheidler VR, Ettinger DS, Diasio RB and Brown MD. Double-Blind Multiple Dose Crossover Study of the Antiemetic Effect of Intramuscular Levonantradol Compared to Prochlorperzine. *J Clin Pharmacol* 24:155, 1984.
66. Markman M, Sheidler V, Ettinger DS, Quaskey SA, and Mellits ED. Antiemetic Efficacy of Dexamethosone: Randomized Double-Blind Crossover Study with Prochlorperzine in Patients Receiving Cancer Chemotherapy. *New Engl J Med* 311:549, 1984.
67. Leichner PK, Klein JL, Fishman EK, Siegelman SS, Ettinger DS, and Order SE. Comparative Tumor Dose from I¹³¹ Labeled Polyclonal Antiferritin, Anti-AFP, and Anti-CEA in Primary Liver Cancer. *Cancer Drug Deliv* 1:321, 1984.
68. Markman M, Sheidler V, Ettinger DS, Quaskey SA, and Mellits ED. Antiemetic Effects of Dexamethasone. *New Engl J Med* 311:1576 (correspondence), 1984.
69. Orr DW, Order SE, and Ettinger DS. Concomitant Doxorubicin and Irradiation for Additive Cytotoxicity in Adrenocortical Carcinoma. *Medical Grand Rounds* 3:250-262, 1984.
70. Abeloff MD, Finkelstein DM, Chang AYC, Camancho FJ, Creech RH, and Ettinger DS. Phase II Study of Aclarubicin and Diaziquone in the Treatment of Advanced Small Cell Bronchogenic Carcinoma (EST 4581): An Eastern Cooperative Group Study. *Cancer Treat Rep* 69:451-452, 1985.
71. Zinreich ES, Ettinger DS, Baker RR, and Order SE. New Frontiers in the Treatment of Lung Cancer. *Crit Rev Onc/Heme* 3:279, 1985.
72. Ettinger DS, Orr DW, Rice AP, and Donehower RC. Phase I Study of N-Methylformamide (NCS-3051) in Patients with Advanced Cancer. *Cancer Treat Rep* 69:489, 1985.
73. Vogelsang GB, Abeloff MD, Ettinger DS, and Booker SV. Long-Term Survivors of Small Cell Carcinoma of the Lung. *Am J Med* 79:49, 1985.
74. Ettinger DS, Finkelstein DM, Harper GR, Ruckdeschel JC, Chang AYC, Camacho FJ, March JC, Silber R, and Wolter JM. A Phase II Study of Mitoxantrone, Aclarubicin, and Diaziquone in the Treatment of Non-Small Cell Lung Carcinoma: An Eastern Cooperative Oncology Group Study. *Cancer Treat Rep* 69:1033, 1985.

75. Moylan DJ, Order SE, Zinreich E, Leibel SA, Spunberg J, Asbel SO, Klein JL, Leichner P, Ettinger, D, and Powers G. Phase I Trial of Radiolabeled Antibody as an Adjuvant to Radiation Therapy for Unresectable Non-Small Cell bronchogenic Carcinoma: A Radiation Therapy Oncology Group Study. *Cancer Treat Symp* 2:109, 1985.
76. Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman S, Fishman E, Ettinger DS, Haulk T, Kopher K, Finney K, Surdyke M, Self S, and Leibel S. ¹³¹I Antiferritin, A New Treatment Modality in Hepatoma: A Radiation Oncology Group Study. *J Clin Oncol* 3:1573, 1985.
77. Pandya KJ, Muggia FM, Skeel RT, Falkson G, Kaplan BM, and Ettinger DS. A Phase II Study of Bisantrone in Advanced Refractory Breast Cancer: An Eastern Cooperative Group Pilot Study. *Am J Clin Oncol* 8:353, 1985.
78. Ettinger DS, Leichner PK, Siegelman SS, Fishman EK, Klein JL, and Order SE. Computed Tomography Assisted Volumetric Analysis of Primary Liver Tumor as a Response to Therapy. *Am J Clin Oncol* 8:413, 1985.
79. Allegra JC, Bertino J, Bonomi P, Byrne P, Carpenter J, Catalano R, Creech R, Dana B, Durivage H, Einhorn L, Ettinger D, et al. Metastatic Breast Cancer: Preliminary Results with Oral Hormonal Therapy. *Semin Oncol* 12:(Suppl. 6):61, 1985.
80. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, and Vogl S. Randomized Trial of the Four Most Active Regimens for Metastatic Non-Small Cell Lung Cancer. *J Clin Oncol* 4:14, 1986.
81. Olver IN, Donehower RC, Van Echo DA, Ettinger DS, and Aisner J. Phase II Trial of Carboplatin in Non-Small Cell Lung Cancer. *Cancer Treat Rep* 70(3):421, 1986.
82. Finkelstein D, Ettinger DS, and Ruckdeschel JC. Long-term Survivors in Metastatic Non-Small Cell Lung Cancer: An Eastern Cooperative Group Study. *J Clin Oncol* 4:702, 1986.
83. Brown TD, Ettinger DS, and Donehower RC. A Phase II Study of Spirohydantoin Mustard (NSC-17211) in Patients with Advanced Cancer. *J Clin Oncol* 4:1270, 1986.
84. Rowinsky EK, Ettinger DS, Grochow LB, Brundrett RB, Cates AE, and Donehower RC. Phase I and Pharmacologic Study of Hexamethylene Bisacetamide in Patients with Advanced Cancer. *J Clin Oncol* 4:1835, 1986.
85. Bonomi PD, Pazdur R, Stolbach L, Mason B, and Ettinger DS. Phase II Trial of Mitomycin, Vindesine and Hexamethylmelamine in Metastatic Bronchogenic Carcinoma. *Cancer Treat Rep* 70:1447, 1986.

86. Donehower RC, Rosenshein NB, Rotmensch J, and Ettinger DS. Sequential Methotrexate and 5-Fluorouracil in Advanced Ovarian Carcinoma. *J Gyn Oncol* 27:90, 1987.
87. Brown TD, Donehower RC, Grochow LB, Rice AP, and Ettinger DS. A Phase I Study of Menogaril in Patients with Advanced Cancer. *J Clin Oncol* 5:92, 1987.
88. Rowinsky EK, Harwood KV, and Ettinger DS. Sudden Dyspnea Occurring Twenty-Four Hours After Receiving Mitomycin Plus Etoposide Combination Chemotherapy. *Cancer Treat Rep* 71:103, 1987.
89. Longnecker SM, Donehower RC, Cates AE, Chen T, Brundrett RB, Grochow LB, Ettinger DS, and Colvin M. High Performance Liquid Chromatographic Assay for Taxol (NSC-125973) in Human Plasma and Urine and Pharmacokinetics in a Phase I Trial. *Cancer Treat Rep* 71:53, 1987.
90. Baker RR, Ettinger DS, Ruckdeschel JC, Eggleston JC, McKneally MF, Abeloff MD, Woll J, and Adelstein DJ. The Role of Surgery in the Management of Selected Patients with Small Cell Carcinoma of the Lung. *J Clin Oncol* 5:697, 1987.
91. Stillwagon GB, Order SE, Klein JL, Leichner PK, Leibel SA, Siegelman SS, Fishman EK, Ettinger DS, Haulk T, Kopher K, Brown SM, and Kinney K. Multi-Modality Treatment of Primary Nonresectable Intrahepatic Cholangiocarcinoma with ¹³¹I Anti-CEA. *Int J Rad Oncol Biol Phys* 13:687, 1987.
92. Rowinsky EK, McGuire WP, Anhalt GJ, Ettinger DS, and Donehower RC. Hexamethylene Bisacetamide (HMBA)-Induced Cutaneous Vasculitis. *Cancer Treat Rep* 71:471, 1987.
93. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Rice AP, and Ettinger DS. Phase I Trial of Taxol (NSC-125973) in Patients with Advanced Cancer. *Cancer Treat Rep* 7(12):1171, 1987.
94. Ettinger DS and Wilcox P. Benign Breast Disorders -- A Symptomatic Approach. *Hospital Practice* 22:75, 1987.
95. Rowinsky EK, Ettinger DS, McGuire WP, Noe DA, Grochow LB and Donehower RC. Prolonged Infusion of Hexamethylene Bisacetamide: A Phase I and Pharmacologic Study. *Cancer Res* 47:5788, 1987.
96. Ettinger DS and Harwood KV. Phase II Study of Recombinant Beta Interferon in Patients with Advanced Non-Small Cell Lung Carcinoma. *Med Pediatr Oncol* 16:30, 1988.
97. Rowinsky EK, Noe DA, Orr DW, Grochow LB, Ettinger DS and Donehower RC. Clinical Pharmacology of Oral and Intravenous N-Methylformamide: A Pharmacologic Basis for Lack of Clinical Antineoplastic Activity. *J Natl Cancer Inst* 80:671, 1988.

98. Beveridge RA, Chan DW, Bruzek D, Damron D, Ettinger DS, Rock RC, Shurbaji MS and Kuhajda FP. A New Biomarker in Monitoring Breast Cancer: CA 549. *J Clin Oncol* 6:1815, 1988.
99. Hantel A, Rowinsky EK, Noe DA, McGuire WP, Grochow LB, Vito BL, Ettinger DS and Donehower RC. Clinical and Pharmacological Reappraisal of Dichloromethotrexate. *J Natl Cancer Inst* 80:1547, 1988.
100. Chan DW, Beveridge RA, Bruzek DJ, Damron DJ, Rock RC, Ettinger DS, Bray KR and Gaur PK. Monitoring Breast Cancer with CA 549. *Clin Chem* 34:2000, 1988.
101. Grochow LB, Noe DA, Dole GB, Ettinger DS, Rowinsky EK, Graham ML, McGuire WP, and Donehower RC. A Phase I Trial of Trimetrexate Glucuronide (NSC 352122) on a 5 Day Bolus Schedule: Clinical Pharmacology and Pharmacodynamics. *J Natl Cancer Inst* 81:124, 1989.
102. Donehower RC, Noe DA, Grochow LB, Hantel A, Rowinsky EK, Vito BL, McGuire WP, and Ettinger DS. Pharmacology of Dichloromethotrexate. *J Natl Cancer Inst* 81:815, 1989 (Letter).
103. Ettinger DS, Finkelstein DN, Donehower RC, Chang AYC, Green M, Blum RH, Hahn RG, and Ruckdeschel JC. Phase II Study of N-Methylformamide, Spirogermanium and 4-Demethoxydaunorubicin in the Treatment of Non-Small Cell Lung Cancer (EST 3583): An Eastern Cooperative Group Study. *Med Pediatr Oncol* 17:197, 1989.
104. McGuire WP, Rowinsky EK, Rosenshein NB, Grumbine FC, Ettinger DS, Armstrong DK, and Donehower RC. Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial Neoplasms. *Ann Int Med* 111:273, 1989.
105. Grochow LB, Noe DA, Ettinger DS, and Donehower RC. A Phase I Trial of Trimetrexate Glucuronate (NSC 352122) Every Three Weeks: Clinical Pharmacology and Pharmacodynamics. *Cancer Chemother Pharmacol* 24:314, 1989.
106. Rowinsky EK, Grochow LB, Hantel A, Ettinger DS, Vito BL, and Donehower RC. Reassessment of N-Methylformamide (NMF) Administered Orally on a Three Times Weekly Schedule: A Phase I Study. *Invest New Drugs* 7:317, 1989.
107. Pedersen AG, Bishop JF, Bleehen NM, Earl H, Ettinger DS, Greco FA, Kristjansen PEG, Postmus PE, and Turrisi AT. Management of CNS Metastases in Small Cell Lung Cancer: A Consensus Report. *Lung Cancer* 5:140, 1989.
108. Rowinsky EK, Burke PJ, Karp JE, Tucker RW, Ettinger DS, and Donehower RC. Phase I and Pharmacodynamic Study of Taxol in Refractory Acute Leukemias. *Cancer Res* 49:4640, 1989.

109. Ettinger DS, Finkelstein DM, Abeloff MD, Ruckdeschel JC, Aisner SC, and Eggleston JC. A Randomized Comparison of Standard Chemotherapy Versus Alternating Chemotherapy and Maintenance Versus No Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer: A Phase III Study of the Eastern Cooperative Oncology Group. *J Clin Oncol* 8:230, 1990.
110. Ettinger DS. Evaluation of New Drugs in Untreated Patients with Small Cell Lung Cancer: Its Time Has Come. *J Clin Oncol* 8:374, 1990.
111. Aisner SC, Finkelstein DN, Ettinger DS, Abeloff MD, Ruckdeschel JC, and Eggleston JC. The Clinical Significance of Variant Morphology Small Cell Carcinoma of the Lung. *J Clin Oncol* 8:402, 1990.
112. Ettinger DS, Finkelstein DM, Abeloff MD, Chang YC, Smith TJ, Oken MM, and Ruckdeschel JC. Phase II Study of N-Methylformamide (NSC 3051) and Spirogermanium (NSC 192965) in the Treatment of Advanced Small Cell Lung Cancer. *Invest New Drugs* 8:175, 1990.
113. Armstrong DK and Ettinger DS. Current Approaches to Treatment of Hypercalcemia of Malignancy. *Mod Med Canada* 45:226, 1990.
114. Schuchter LM, Hendricks CB, Holland KH, Sheldon BK, Hutchins GM, Baughman KL, and Ettinger DS. Eosinophilic Myocarditis Associated with High Dose Interleukin-2 Therapy. *Am J Med* 88:439, 1990.
115. Hantel A, Donehower RC, Rowinsky EK, Vance E, Clarke BV, McGuire WP, Ettinger DS, and Grochow LB. A Phase I and Pharmacokinetic Trial of Piroxantrone (NSC 349174), A New Anthrapyrazole. *Cancer Res* 50:3284, 1990.
116. Kennedy MJ, Donehower RC, Grochow LB, Ettinger DS, Fetting JH, and Abeloff MD. Phase II Trial of Menogaril as Initial Chemotherapy for Metastatic Breast Cancer. *Invest New Drugs* 8:289, 1990.
117. Noe DA, Rowinsky EK, Shen HL, Clarke BV, Grochow LB, McGuire WB, Hantel A, Adams DB, Abeloff, MD, Ettinger DS, and Donehower RC. Phase I and Pharmacokinetic Study of Brequinar Sodium (NSC 368390). *Cancer Res* 50:4595, 1990.
118. Ettinger DS, Bitran JD, Comis RL, Langer CJ, Harwood KV, Harris CL, Keller JH, and Losada MA. Phase I-II Evaluation of Etoposide and Mitomycin in the Treatment of Non-Small Cell Lung Cancer. *Am J Clin Oncol* 14:127, 1991.
119. Holmes EC, Bleehan MM, LeChevalier T, Ettinger D, Jett JR, Johnson D, Komaki R, Saijo N, Sause W, Trovo M, Van Houtte P, and Wulfrank D. Postoperative adjuvant treatments for non-small cell lung cancers: a consensus report. *Lung Cancer* 7:11, 1991.

120. Ettinger DS. New Drugs in the Treatment of Non-Small Cell Lung Cancer. *Lung Cancer* 7:113, 1991.
121. Order S, Pajak T, Leibel S, Asbell S, Leichner P, Ettinger D, Stillwagon G, Herpst J, Haulk T, Kopher, K, Frazier C, and Klein J. A Randomized Prospective Trial Comparing Full Dose Chemotherapy to ¹³¹I Antiferritin: An RTOG Study. *Int J Rad Oncol Biol Phys* 20:953, 1991.
122. Ettinger DS, (Article Reviewed) Ifosfamide vs. Cyclophosphamide in cancer therapy. Weiss R, *Oncology* 5:84, 1991.
123. Ettinger DS. Evaluation of alternating chemotherapy in patients with small cell lung cancer. A commentary. *Lung Cancer* 7:253, 1991.
124. Hendricks CB, Grochow LB, Rowinsky EK, Forastiere AA, McGuire WP, Ettinger DS, Sartorius S, Lubejko B and Donehower RC. Phase I and Pharmacokinetic Study of Hepsulfam (NSC 329680). *Cancer Res* 51:5781, 1991.
125. Epstein B, Ettinger D, Leichner PK, and Order SE. Multimodality Cisplatin Treatment in Nonresectable Alphafetoprotein Positive Hepatoma. *Cancer* 67:896, 1991.
126. Stillwagon GB, Order ST, Haulk T, Herpst J, Ettinger DS, Fishman EK, Klein JL, Leichner PK. Variable Low Dose Rate Treatment Irradiation (¹¹³I-Anti-CEA) and Integrated Low Dose Chemotherapy in the Treatment of Nonresectable Primary Intrahepatic Cholangiocarcinoma. *Int J Rad Oncol Biol Phys* 21:1601, 1991.
127. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB, and Donehower RC. Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study. *J Clin Oncol* 9:1692, 1991.
128. Miller CB, Platania LC, Mills SR, Zahurak ML, Ratain MJ, Ettinger DS, and Jones RJ. Phase I-II Trial of Erythropoietin in the Treatment of Cisplatin-Associated Anemia. *J Natl Cancer Inst* 84:98, 1992.
129. Rowinsky EK, Grochow LB, Hendricks CB, Ettinger DS, Forastiere AA, Hurowitz LA, McGuire WP, Sartorius SE, Lubejko BG, Kaufmann SH, and Donehower RC. Phase I and Pharmacologic Study of Topotecan. A Novel Topoisomerase I Inhibitor. *J Clin Oncol* 10:647, 1992.
130. Ettinger DS, Finkelstein DM, Abeloff MD, Skeel RT, Stott PB, Frontiera MS, and Bonomi PD. Justification for Evaluating New Anticancer Drugs in Selected Untreated Patients with Extensive-Stage Small Cell Lung Cancer: An Eastern Cooperative Oncology Group Randomized Study. *J Natl Cancer Inst* 84:1077, 1992.

131. Enterline JP, Majidi FM, Ogorzalek LL, Stuart G, Rauch JS, Fulton MD, and Ettinger DS. Integrated Ambulatory Care Services in Oncology. *Proc Annu Symp Comput Appl Med Care* 197, 1992.
132. Majidi F, Enterline JP, Ashley B, Fowler ME, Ogorzalek LL, Gaudette r, Stuart GJ, Fulton M, Ettinger DS. Chemotherapy and Treatment Scheduling: The Johns Hopkins Oncology Center Outpatient Department. *Proc Annu Symp Comput Appl Med Care* 154, 1993.
133. Grossman SA, Finkelstein D, Ruckdeschel JC, Trump DL, Moynihan T, and Ettinger DS. Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. *J Clin Oncol* 11:561, 1993.
134. Rowinsky EK, Noe DA, Ettinger DS, Christian MC, Lubejko BG, Fishman EK, Sartorius SE, Boyd MR, and Donehower RC. Phase I and Pharmacological Study of the Pulmonary Cytotoxin 4-Ipomeanol on a Single Dose Schedule in Lung Cancer Patients. Hepatotoxicity is Dose Limiting in Humans. *Cancer Res* 53:1794, 1993.
135. Johnson DH, Turrisi AT, Chang AY, Blum R, Bonomi P, Ettinger D, and Wagner H. Alternating Chemotherapy and Twice-Daily Thoracic Radiotherapy in Limited-Stage Small Cell Lung Cancer. A Pilot Study of the Eastern Cooperative Oncology Group. *J Clin Oncol* 11:879, 1993.
136. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Noe DA, and Donehower RC. A Phase I and Pharmacologic Study of Taxol and Cisplatin with Granulocyte Colony-Stimulating Factor: Neuromuscular Toxicity is Dose-Limiting. *J Clin Oncol* 11:2010, 1993.
137. Ettinger DS. Taxol in the Treatment of Lung Cancer. *J Natl Cancer Inst (Monographs)* No. 15:177, 1993.
138. Rowinsky EK, Noe DA, Trump DL, Winer EP, Lucas VS, Wargin WA, Hohnaker JA, Lubejko B, Sartorius SE, Ettinger DS, et al. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors. *J Clin Oncol* 12:1754, 1994.
139. Bonomi PD, Finkelstein DM, Aisner S, and Ettinger DS. EST 2582 Phase II Trial of Cisplatin in Metastatic or Recurrent Thymoma. *Am J Clin Oncol* 16:342, 1994.
140. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, Chen TL, Rock M and Donehower RC. Phase I and Pharmacologic Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1piperdino) Carbonyloxy Camptothecin (CPT-11) Administered as a 90 Minute Infusion Every 3 Weeks. *Cancer Res* 54:427, 1994.
141. Schiller JH, Ettinger DS, Larson M, Gradisher W, Merkel D and Johnson DH. Phase II Trial of Oral Etoposide Plus Cisplatin in Extensive Stage Small Cell Carcinoma of the Lung: An Eastern Cooperative Group Study. *Eur J Cancer* 30A:158, 1994.

142. Lenhard RE, Daniels MJ, Oken MM, Glick JH, Ettinger DS, Kalish L and O'Connell MJ. An Aggressive High Dose Cyclophosphamide and Prednisone Regimen for Advanced Multiple Myeloma. *Leuk Lymphoma* 13:485, 1994.
143. Lenhard RE, Kalish LA, Oken MM, Ettinger DS and Glick J. Timed Sequential High-Dose Cyclophosphamide and Vincristine in the Treatment of Multiple Myeloma. *Cancer* 73:2113, 1994.
144. Borkowski JM, Duerr M, Donehower RC, Rowinsky E, Chen TL, Ettinger DS, and Grochow LB. Relation Between Age and Clearance Rate of Nine Anticancer Drugs from Phase I Pharmacokinetic Data. *Cancer Chemother and Pharmacol* 33:493, 1994.
145. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Scotte Doggett RL, Coughlin C, Scarantino C, Rotmann M and Emami B. Concurrent Hyperfractionated Irradiation and Chemotherapy for Unresectable Non-Small Cell Lung Cancer: Results of Radiation Therapy Oncology Group (RTOG) 90-15. *Cancer* 75:2337, 1995.
146. Ettinger DS, Finkelstein DM, Sarma RP and Johnson DH. Phase II Study of Paclitaxel in Patients with Extensive-Disease Small Cell Lung Cancer: An Eastern Cooperative Group Study. *J Clin Oncol* 13:1430, 1995.
147. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD and Johnson DH. A Phase II Study of Ifosfamide, Carboplatin, and Oral Etoposide Chemotherapy for Extensive-Disease Small Cell Lung Cancer: An Eastern Cooperative Oncology Group Pilot Study. *J Clin Oncol* 13:1615, 1995.
148. Ettinger DS, Eisenberg PD, Fitts D, Friedman C, Wilson-Lynch K and Yocom K. A Double-Blind Comparison of the Efficacy of Two Dose Regimens of Oral (1 mg twice, 2 mg once) in Preventing Acute Emesis in Patients Receiving Moderately Emetogenic Chemotherapy. *Cancer* 78:145, 1996.
149. Rowinsky EK, Kaufmann SH, Grochow LB, Chen T-L, Peereboon D, Bowling MK, Sartorius SE, Ettinger DS, Forastiere AA and Donehower RC. Sequences of Topotecan and Cisplatin: Phase I, Pharmacologic and In Vitro Studies to Examine Sequence-Dependence. *J Clin Oncol* 14:3074, 1996.
150. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen T-L, Sartorius S, Bowing K, Lubejko B, Ignacio V and Grochow LB. Phase I and Pharmacologic Studies of Topotecan in Patients with Impaired Hepatic Function. *J Natl Cancer Inst* 88:817, 1996.
151. O'Reilly S, Rowinsky EK, Slichenmyer W, Donehower RC, Forastiere AA, Ettinger DS, Chen T-L, Sartorius S and Grochow LB. Phase I and Pharmacologic Study of Topotecan in Patients with Impaired Renal Function. *J Clin Oncol* 14:3062, 1996.

152. Rowinsky EK, Flood WA, Sartorius SE, Bowling KM and Ettinger DS. Phase I Study of Paclitaxel on a 3-hour Schedule Followed by Carboplatin in Untreated Patients with Stage IV Non-Small Cell Lung Cancer. *Invest New Drugs* 15:129, 1997.
153. White P and Ettinger DS. Tissue Is the Issue: Is Endoscopic Ultrasonography With or Without Fine-Needle Aspiration Biopsy in the Staging of Non-Small Cell Lung Cancer an Advance? *Ann Int Med* 127:643, 1997 (Editorial).
154. Tucker MA, Murray N, Shaw EG, Ettinger DS, Mabry M, Huber MH, Feld R, Shepard FA, Johnson DH, Grant SC, Aisner J and Johnson BE for the Lung Cancer Working Cadre. Second Cancers Related to Smoking and the Treatment for Small Cell Lung Cancer. *J Natl Cancer Inst* 89:1782, 1997.
155. Gregory RE and Ettinger DS. 5-HT₃ Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting. *Drugs* 55:173, 1998.
156. Kalemkerian GP, Jiroutek M, Ettinger DS, Dorigi JA, Johnson DH and Mabry M. Phase II Study of All-Trans-Retinoic Acid Plus Cisplatin and Etoposide in Extensive Stage Small Cell Lung Carcinoma: An Eastern Cooperative Oncology Group Study (E2593). *Cancer* 83:1102, 1998.
157. Langer CJ and Ettinger DS. The Burgeoning Role of Paclitaxel in Advanced Pulmonary Malignancy. *The Oncologist* 3:67, 1998.
158. Hermann JF, Ettinger DS and Gams R. The Final Dilemma. End-of-Life Treatment Decisions. *Cancer Practice* 6:57, 1998.
159. Brahmer J and Ettinger DS. The Role of Topotecan in Small Cell Lung Cancer. *The Oncologist* 3:11, 1998.
160. Brahmer J and Ettinger DS. Carboplatin in the Treatment of Small Cell Lung Cancer. *The Oncologist* 3:143, 1998.
161. Belani CP, Bonomi P, Dobbs TW, DeVore RF, Ettinger DS, Jett J, Luketich JD, Cohen LJ and Johnson DH. Docetaxel and Cisplatin in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Multicenter Phase II Trial. *Clin Lung Cancer* 1:144, 1999.
162. Lin K, Nguyen BD, Ettinger DS and Chin BB. Somatostatin Receptor Scintigraphy and Somatostatin Therapy in the Evaluation and Treatment of Malignant Thymoma. *Clin Nucl Med* 24:24, 1999.
163. Yuen A, Fuks JZ, Ettinger DS, Chang AY, Ruckdeschel JC, Phan SC and Blum RH. Pilot Study with Weekly Chemotherapy for Patients with Extensive Small Cell Lung Cancer: An Eastern Cooperative Group Study (PA 586). *Cancer J Sci Am* 6:34, 2000.

164. Ettinger DS. Gemcitabine Plus Radiation Therapy in the Treatment of Locally Advanced Non-Small Cell Lung Cancer. *Clin Lung Cancer* 2(Suppl 1) 533, 2000.
165. Hahn HA, Ettinger DS, Bowling K, Hoker B, Chent T-L, Zabelina Y, Olson S, and Casero RA Jr. Phase I Study of N1-N11-Diethylnorspermine (DENSPM) in Patients with Non-Small Cell Lung Cancer (NSCLC). *Clin Cancer Res* 8:684, 2002.
166. Ettinger DS. Is There a Preferred Combination Chemotherapy Regimen for Metastatic Non-Small Cell Lung Cancer? *The Oncologist* 7:226, 2002.
167. Spira AI and Ettinger DS. The Use of Chemotherapy in Soft-Tissue Sarcomas. *The Oncologist* 7:348, 2002.
168. Ettinger DS, Finkelstein DM, Ritch PS, Lincoln ST and Blum RH. Phase II-III Study of Chemotherapy of Extensive Disease Small Cell Lung Carcinoma of the Lung: An Eastern Cooperative Oncology Group Randomized Study (E1588). *Lung Cancer* 37:311, 2002.
169. Lee JS, Scott CB, Komaki R, Ettinger DS, Sause WT. Impact of institutional experience on survival outcome of patients undergoing combined chemoradiation therapy for inoperable non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* 52:362-70, 2002.
170. Komaki R, Seiferheld W, Ettinger D, Lee LS, Movsas B, Sause W. Randomized Phase II Chemotherapy and Radiotherapy Trial for Patients with Locally Advanced Inoperable Non-Small-Cell Lung Cancer: Long-Term Follow-up of RTOG 92-04. *Int J Radiat Oncol Biol Phys* 53:548, 2002.
171. Johnstone DW, Byhardt RW, Ettinger D, Scott CB. Phase III Study Comparing Chemotherapy and Radiotherapy with Preoperative Chemotherapy and surgical resection in patients with non-small lung cancer with spread to mediastinal lymph nodes (N2); final report of RTOG 89-01. Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 54:365, 2002.
172. Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, Goldberg M, Graham M, Ettinger D, Johnstone D, Abrams R, Munden R, Starkschall G, Owen J. Radiotherapy Patterns of Care Study in Lung Carcinoma. *J Clin Oncol* 21:4553-4559, 2003.
173. Loehrer PJ, Wang W, Johnson D, Ettinger DS. Octreotide Alone or With Prednisone in Patients With Advanced Thymoma and Thymic Carcinoma. *J Clin Oncol* 22:293, 2004.
174. Spira AI and Ettinger DS. Multidisciplinary Management of Lung Cancer. *N Eng J Med* 350:379, 2004.

175. Monnerat C, LeChavalier TL, Kelly K, Obasaju C, Brahmer J, Novello S, Nakamura T, Liepa AM, Bozec L, Bunn P and Ettinger DS. Phase II Study of Pemetrexed-Gemcitabine Combination in Patients with Advanced Stage Non-Small Cell Lung Cancer. *Clin Can Res* 10:5439, 2004.
176. Brock MV, Hooker CM, Syphard JE, Westra W, Xu L, Alberg AJ, Mason D, Baylin SB, Herman JG, Yung RC, Brahmer J, Rudin CM, Ettinger DS, Yang SC. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. *J Thorac Cardiovasc Surg* 129:64-72, 2005.
177. Langer CJ, Moughan J, Movsas B, Komaki R, Ettinger D, Owen J, Wilson JF. Patterns of Care Survey (PCS) in Lung Cancer: How Well Does Current U.S. Practice with Chemotherapy in the Non-Metastatic Setting Follow the Literature? *Lung Cancer* 48:93-102, 2005.
178. Okuno S, Maples WJ, Mahoney MR, Fitch T, Stewart J, Fracasso PM, Kraut M, Ettinger DS, Dawkins F, and Erlichman C. Evaluation of epothilone B analog in advanced soft tissue sarcoma: A phase II study of the phase II consortium. *J Clin Oncol* 23:3069-3073, 2005.
179. Bradley J, Paulus R, Graham M, Ettinger DS, Bradley J, Pilepich MV, Machtay M, Komaki R, Adkins JN, Curran W. A Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small Cell Lung Cancer – Promising Long Term Results of a Radiation Therapy Oncology Group Trial – RTOG 9705. *J Clin Oncol* 23:3480-3487, 2005.
180. Komaki R, Swann S, Ettinger D, Glisson B, Sandler A, Movsas B, Suh J, Byhardt R. Phase I Study of Thoracic Radiation Dose Escalation with Concurrent Chemotherapy for Patients with Limited Small Cell Lung Cancer: Report of Radiation Therapy Oncology Group (RTOG) Protocol 97-12. *Int J Radiation Oncology Biol Phys* 62:342-350, 2005.
181. Ettinger DS, Berkey BA, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ, Movsas B, Byhardt RW. Study of Paclitaxel, Etoposide and Cisplatin Chemotherapy Combined with Twice Daily Thoracic Radiotherapy for Patients with Limited Stage Small Cell Lung Cancer: An RTOG 9609 Phase II Study. *J Clin Oncol* 23:4991-4998, 2005.

Articles Published in Non-Peer Reviewed Professional Journals

1. Ettinger DS, Allegra J, Bertino J, Bonomi P, Browder H, Byrne P, Carpenter J, Catalano R, Creech, R, Dana B, Durivage H, Einhorn L, Greco FA, Greenwald E, Henderson I, Holmes F, Keller J, Kinzbrunner B, Losada M, Luedke S, Muss H, Nimeh N, Wampler G, Weinreb N, Weisberg J, Wheeler R, and Wiernik PH. Megestrol Acetate vs. Tamoxifen in Advanced Breast Cancer: Correlation of Hormone Receptors and Response. *Semin Oncol* 13(Suppl.4):9, 1986.

2. Ettinger DS. Ifosfamide in the Treatment of Non-Small Cell Lung Cancer, *Semin Oncol 16(Suppl 3):31*, 1989.
3. Ettinger DS. Systemic and Combined-Modality Therapy for Lung Cancer. *Md Med J 39:315*, 1990.
4. Ettinger DS. Overview of Ifosfamide in Small Cell Lung Cancer. *Semin Oncol 19(Suppl 1):59*, 1992.
5. Ettinger DS. Lung and Mediastinum: editorial overview. *Curr Opin Oncol 5:291*, 1993.
6. Ettinger DS. Metastatic Non-small Cell Lung Cancer. *Lung Cancer 9(Suppl 2):69*, 1993.
7. Ettinger DS. Overview of Paclitaxel (Taxol) in Advanced Lung Cancer. *Semin Oncol 20(Suppl 3):46*, 1993.
8. Johnson DH, Chang AY and Ettinger DS. Taxol (Paclitaxol) in the Treatment of Lung Cancer: The Eastern Cooperative Oncology Group Experience. *Ann Oncol, 5(Suppl 6):S45*, 1994.
9. Ettinger DS. The Place of Ifosfamide in Chemotherapy of Small Cell Lung Cancer: The ECOG Experience and a Selected Literature Update. *Semin Oncol 22(Suppl 2):23*, 1995.
10. Ettinger DS. New Drugs for Treating Small Cell Lung Cancer. *Lung Cancer 12(Suppl 3):S53*, 1995.
11. Rowinsky EK, Flood WA, Sartorius SE, Bowling MK, Wagner J and Ettinger DS. Phase I Study of Paclitaxel as a 3-hour Infusion Followed by Carboplatin in Untreated Patients with Stage IV Non-Small Cell Lung Cancer. *Semin Oncol 22(Suppl 9):48*, 1995.
12. Ettinger DS. Preventing Chemotherapy-Induced Nausea and Vomiting: An Update and a Review of Emesis. *Semin Oncol 22(Suppl 10):6*, 1995.
13. Ettinger DS, Panel Chairman. NCCN Non-Small Cell Lung Cancer Practice Guidelines. *Oncology 10 (Suppl):81*, 1996.
14. Ettinger DS, Panel Chairman. NCCN Antiemesis Practice Guidelines. *Oncology 11:57*, 1997.
15. Ettinger DS. Combined Modality Treatment for Stage IIIa (N₂) Non-Small Cell Lung Cancer: A National Cancer Institute Intergroup Study. *Cancer Chem Pharm 42(Suppl):571*, 1998.
16. Ettinger DS. The Role of Carboplatin in the Treatment of Small Cell Lung Cancer. *Oncology 12(Suppl 2):36*, 1998.

17. Ettinger DS, Panel Chairman. NCCN Practice Guidelines for Occult Primary Tumors. *Oncology* 12:226, 1998.
18. Ettinger DS. Concurrent Paclitaxel-Containing Regimens and Thoracic Radiation Therapy for Limited-Disease Small Cell Lung Cancer. *Semin Rad Onc* 9(*No. 2, Suppl 1*):148, 1999.
19. Ettinger DS. Panel Chairman. NCCN Practice Guidelines for Neuroendocrine Tumors. *Oncology* 13:297, 1999.
20. Ettinger DS. Gemcitabine/Alimta in Locally Advanced or Metastatic Non-Small Cell Lung Cancer. *Oncology* 14(*Suppl 4*):49, 2000.
21. Ettinger DS. New drugs for chemotherapy-naïve patients with extensive-disease small cell lung cancer. *Semin Oncol* 28(2 *Suppl 4*):27, 2001.
22. Ettinger DS. NCCN: Non-Small Cell Lung Cancer Practice Guidelines Panel. *Cancer Control* 8(*Suppl 2*):22, 2001.
23. Ettinger DS. Pemetrexed (Alimta®): A New Antifolate for Non-Small-Cell Lung Cancer. *Clinical Lung Cancer* 3(*Suppl 1*):S22, 2002.
24. Purcell WT, Ettinger DS. Novel Antifols. *Curr Oncol Rep* 5(2):114-25, 2003.
25. Spira A, Ettinger DS. Extensive-stage small-cell lung cancer. *Semin Surg Oncol* 21:164-175, 2003.
26. Ettinger DS. Overview and State of the Art Management of Lung Cancer. *Oncology* 18(*Suppl 4*):3, 2004.
27. Ettinger DS. Treatment of Bone Metastases as a Disease State in Non-Small-Cell Lung Cancer. *New Directions in the Treatment of Lung Cancer*, Pass HI and Johnson DH (eds), 1:1-7, 2004.
28. Ettinger DS. Non-Small Cell Lung Cancer Treatment-Related Bone Marrow Toxicities. *Semin Oncol* 32(2 *Suppl 3*):S81-85, 2005.
29. Ettinger DS. An Overview of Eastern Cooperative Oncology Group Stage II Non-Small Cell Lung Cancer Studies. *Semin Oncol* 32(2 *Suppl 3*):S109-110, 2005.
30. Balducci L, Cohen HJ, Engstrom PF, Ettinger DS, Halter J, Gordon LI, Kiel K, Kneier A, Lim D, Petersdorf SH, Rosenthal R, Silliman r, Vose JM, Walker MJ, Zachariah B. Senior Adult Oncology. *J Natl Compr Canc Netw* 3:572-590, 2005.

Book Chapters

1. Order SE, Klein JL, Ettinger DS, Wharam MD, Humphrey R, Siegelman SS, Garrison JB, Jenkins RE, Wallace J, and Leichner P. Quantitation of Isotopic Immunoglobulin Therapy to Tumor Associated Proteins. Ch. 26. Saunders JP, Daniels JC, Serrou B, Rosenfeld C, and Denney, C.B., eds. In Fundamental Mechanisms in Human Cancer Immunology. Vol. 5. Elsevier, North Holland, New York. 359-374, Sept. 1981.
2. Order SE, Klein JL, Ettinger DS, Alderson P, Siegelman S, Leichner P. Radiolabeled Antibody to Tumor-Associated Proteins. Terry W, Rosenberg S, eds., In Immunotherapy of Human Cancer. Elsevier, North Holland, Inc., New York. 485-494, 1982.
3. Order SE, Klein JL, Leichner PK, Wharam MD, Chambers J, Kopher K, Ettinger DS, and Siegelman SS. Radiolabeled Antibodies in the Treatment of Primary Liver Malignancies. In Gastrointestinal Cancer. Levin & Riddell, eds., Elsevier, North Holland, Inc., New York, 222-232, 1984.
4. Ettinger DS. Management of Disseminated Breast Cancer. In Current Surgical Therapy 1984-1985, Cameron J, ed., B.C. Decker, Inc., Ontario, Canada, 346-355, 1984.
5. Ettinger DS. Chemotherapy of Lung Cancer. In Current Therapy in Hematology-Oncology 1985-1986, Brain MC, Carbone PP, eds. B.C. Decker, Inc. Ontario, Canada, 193-196, 1985.
6. Order SE, Klein JL, Leichner PK, Ettinger DS, Kopher K, Finney K, Surdyke M, and Leibel SA. Radiolabeled Antibody in the Treatment of Primary and Metastatic Liver Malignancies. In Recent Results in Cancer Research. Therapeutic Strategies in Primary and Metastatic Liver Cancer. Vol. 100. Springer-Verlag, Heidelberg, Germany, 307-314, 1986.
7. Ettinger DS. The Clinical Use of Antiemetics. In Clinical Psychopharmacology. Derogatis, L.R., ed. Addison-Wesley Publishing, Inc. Reading, Massachusetts, 248-268, 1986.
8. Ettinger DS. Chemotherapy in Head and Neck Cancer. In Complications in Otolaryngology, Head and Neck Surgery, Johns ME, ed., Volume 2, Head and Neck. B.C. Decker, Ontario, Canada, 227-234, 1986.
9. Ettinger DS. Chemotherapy of Lung Cancer. In Current Therapy in Internal Medicine - 2, Bayless TM, Brain MC, Cherniack RM, eds. B.C. Decker, Inc., Ontario, Canada. 408-411, 1987.
10. Abeloff MD and Ettinger DS. Diagnosis and Management of Medical and Surgical Problems in the Patient with Lung Cancer. In Lung Cancer: A Comprehensive Textbook, Bitran JC, Golomb HM, eds. Grune & Stratton, Inc., Orlando, Florida. 411-438, 1988.

11. Order SE, Stillwagon G, and Ettinger DS. The Management of Primary Liver Cancers. In Current Therapy in Hematology-Oncology 1991-1992, Brain MD, Carbone PP, eds. B.C. Decker, Inc., Ontario, Canada, 265-269,1992.
12. Ettinger DS. Small Cell Lung Cancer. In Current Therapy in Oncology. Niederhuber JD, ed. B.C. Decker, Inc., Ontario Canada, 182-188, 1992.
13. Ettinger DS. (Commentary) Oncology: Molecular Biology is the Wave of Future. In Medicine: The Year in Review, 1993 Edition, Medical Tribune Inc., New York, New York, 247, 1993.
14. Slichenmyer WJ and Ettinger DS. Metabolic Complications of Cancer. In Handbook of Medical Supportive Care in Cancer, Klastersky J, Schimpff SC, Senn HJ, eds. Marcel Dekker Inc., New York, New York, 335-364, 1995.
15. Ettinger DS. Paclitaxel (Taxol) in the Treatment of Small Cell Lung Cancer. In Paclitaxel In Cancer Treatment. McGuire W and Rowinsky EK, eds. Marcel Dekker Inc, New York, New York, 281-286, 1995.
16. Rowinsky EK and Ettinger DS. Drug Development and New Drugs. In Lung Cancer: Principles and Practice. Pass HI, Mitchel J, Johnson DH, and Turrisi AT eds. J.B. Lippincott Co., Philadelphia, Pennsylvania, 1995.
17. Armstrong DK and Ettinger DS. The Management of Disseminated Breast Cancer. In Current Surgical Therapy 1994-1995. Cameron J ed. BC Decker, Inc., Ontario, Canada, 565-570, 1995.
18. Ettinger DS. Paclitaxel in the Treatment of Small Cell Lung Cancer - The North American Experience. In Taxanes in Lung Cancer. Johnson DH and Klastersky J eds. Marcel Dekker, Inc., New York, New York 1997.
19. Contributor to Atlas of Internal Medicine. Eugene Braunwald, ed., Current Medicine Inc., Philadelphia, Pennsylvania, 1998.
20. Brahmer JR, Kleinberg L and Ettinger DS. Combined Modality Treatment of Small-Cell Lung Cancer. In Chemoradiation in Cancer Therapy. Choy H ed. Cancer Drug Discovery and Development Series. Humana Press, Totowa, New Jersey, 2003.
21. Purcell WT, Brahmer JR and Ettinger DS. Chemotherapy for Lung Cancer. In Current Therapy in Thoracic and Cardiovascular Surgery. Yang SC and Cameron DE eds. Mosby, Inc., Philadelphia, Pennsylvania, 291-201, 2004.

Monographs, Videotapes, Audiotapes, etc.

1. Ettinger DS. Disseminated Breast Cancer/Chemotherapy for program entitled Options in the Management of Breast Cancer IV - Disseminated Breast Cancer. SurgSat Video Course in Surgery, 1983.
2. Ettinger DS. The Role of Chemotherapy in Non-Small Cell Lung Cancer. Monograph, Bristol-Myers Oncology Division, New York, 1986.
3. Ettinger DS, Mundy GR, Recker RR, Ritch PS, Singer, FR, and Townsend DC. Hypercalcemia of Malignancy Treatment Goals and Therapeutic Options, Monograph, Excerpta Medica, New Jersey, 1989.
4. Ettinger DS. Metabolic Complications in Cancer Patients (Editorial). ICSCO Reviews N°3:1-3, 1990.
5. Ettinger DS (Chairman), Higby DJ, Lind MJ, Nichols CR, Shepard FA, and Zandwijk NV. Current Developments with Ifosfamide in Non-Small Cell and Small Cell Lung Cancer: A Panel Discussion-Audiotape, 1990.
6. Curran WJ, Ettinger DS, Lee JS and Sause WT. Non-Small Cell Lung Cancer: Combined Modality Therapy Practice Guidelines for the Community Oncologist, 1996.
7. Ettinger DS and Kleinberg LR. Clinical Stimulations in the Management of Oncology Patients, Medical Age Publishing, Norwalk, Connecticut, 1996.
8. Ettinger DS. Small Cell Lung Cancer. The Emerging Role of Topotecan. SmithKline Beecham, 1997.
9. Ettinger DS. The Role of Carboplatin in the Treatment of Small Cell Lung Cancer. Bristol Myers Squibb, 1997.

Invited Participant in International Workshops and Meetings

1. International Association for the Study of Lung Cancer (I.A.S.L.C.) Workshop on Small Cell Carcinoma of the Lung. Ashford Castle, Ireland, September 9-12, 1981.
2. I.A.S.L.C. Second Workshop on Small Cell Lung Cancer. Gleneagles, Scotland, September 9-14, 1984.
3. Third International Conference on the Management of Hormone Responsive Diseases. Rotterdam, The Netherlands, June 7, 1986.
4. I.A.S.L.C. Non-Small Cell Lung Cancer Workshop. Key Biscayne, Florida, November 6-10, 1987.

5. Current Developments and Future Directions with Ifosfamide. Satellite Symposium of the European Society of Medical Oncology. Lugano, Switzerland, October 31, 1988.
6. I.A.S.L.C. Third Workshop on Small Cell Lung Cancer. Copenhagen, Denmark, June 18-June 22, 1989.
7. International Congress on Strategies for Care in Oncology: Supportive Care for the Cancer Patient. Baltimore, Maryland, August 22-25, 1989.
8. I.A.S.L.C. Non-Small Cell Lung Cancer Workshop. Bruges, Belgium, June 17-21, 1990.
9. Current Developments and Future Directions with Ifosfamide: An Update. Satellite Symposium of the European Society of Medical Oncology. Copenhagen, Denmark, December 2, 1990.
10. Non-Small Cell Lung Cancer. Satellite Symposium of the Sixth World Conference on Lung Cancer, Melbourne, Australia, November 10-14, 1991.
11. Platinum-Based Chemotherapy in Lung Cancer: Satellite Symposium of Current Perspectives in Lung Cancer, Tokyo, Japan, June 18-19, 1993.
12. Taxol: Satellite Symposium of the Oncology Congress in Argentina. Buenos Aires, Argentina, August 31-September 3, 1993.
13. Satellite Symposium in Taxol of the 7th Panhellenic Oncology Conference, Athens, Greece, November 4-7, 1993.
14. Second International Asia Pacific Ifosfamide Satellite Symposium of the 11th Asia Pacific Cancer Conference, Bangkok, Thailand, November 16-19, 1993.
15. Seventh International Symposium of the Foundation of Cancer Research. Fundamental and Clinical Research in Lung Cancer, Tokyo, Japan, March 8-10, 1994.
16. IASLC 7th World Conference in Lung Cancer, Colorado Springs, Colorado, June 26-30, 1994.
17. Taxol (Paclitaxel): A Major Advance in Chemotherapy. Symposium of the Growth Control and Therapy of Cancer Conference. Semmelweis University, Budapest, Hungary, August, 1994.
18. 12th Asia Pacific Cancer Conference, Singapore, October 17-20, 1995.
19. University of Colorado Cancer Center Conference, A Recent Developments and Future Directions with Gemcitabine in Lung Cancer, @ Marbella, Spain, August 8-11, 1996.

20. 2nd International Congress on Nuclear Oncology, Naples, Italy, September 23-24, 1996.
21. Clinical Experience with Gemcitabine: A New Treatment for Solid Tumors. Satellite Symposium of the 13th Asia Pacific Cancer Conference, Penang, Malaysia, November 17-20, 1996.
22. IASLC 8th World Conference in Lung Cancer, Dublin, Ireland, August 10-15, 1997.
23. Visiting Professor, Department of Oncology, First Military Medical University, Nanfang Hospital, Guangzhou, China, August 9-11, 1998.
24. Santa Klaus Symposium in Lung Cancer, Lapland, Finland, December 1-3, 1998.
25. Prognostic and Predictive Factors: First International Workshop in Lung Cancer, Athens Vouliagmeni, Greece, June 17-19, 1999.
26. Medical Oncology Group National Conference 2000, Sidney, Australia, April 26-29, 2000.
27. IASLC 9th World Conference on Lung Cancer, Tokyo, Japan, September 10-15, 2000.
28. IASLC 10th World Conference on Lung Cancer, Vancouver, Canada, August 10-14, 2003.
29. Chinese AntiCancer Association Meeting – NCCN Day, Hangzhou, China, September 23-27, 2002.
30. 44th Annual Japan Lung Cancer Society Meeting, Tokyo, Japan, November 5-8, 2003.
31. Asian Pacific Society of Respiriology, 9th Congress Hong Kong December 10-13, 2004, “Parallel Session” – Adjuvant Chemotherapy in Resectable Lung Cancer; “Plenary Lecture 3” – Current Paradigms in the Treatment of Advanced NSCLC.

Abstracts

1. Abeloff MD, Ettinger DS, Inalsingh A, and Hazra TA. Combination Chemotherapy of Small Cell Carcinoma of the Lung. *Proc Am Assoc Cancer Res* 16:80, 1975.
2. Baylin SB, Tomford JW, Ettinger DS, and Abeloff MD. Elevated Histaminase (Diamine Oxidase) Activity in Small Cell Carcinoma of the Lung. *Clin Res* 23 (No. 3):366A, 1975.
3. Abeloff MD and Ettinger DS. Treatment of Metastatic Breast Cancer with Adriamycin + Cytosan Induction Followed by Alternating Combination Therapy. *Proc Am Soc Clin Oncol* 18:273, 1977.

4. Ettinger DS, Baylin SB, Minaberry D, and Abeloff MD. Response of Plasma Histaminase Activity (PHA) to Heparin in Patients with Small Cell Carcinoma of the Lung (SCC). *Proc Am Assoc Cancer Res* 18:170, 1977.
5. Ettinger DS, Abeloff MD, Karp JE, Burke PJ, and Braine HG. Intensive Chemotherapy for Small Cell Carcinoma of the Lung (SCC). Second National Cancer Institute Conference on Lung Cancer Treatment, No. 16, 1977.
6. Abeloff MD, Ettinger DS, Wharam MD, and Order SE. Treatment Simulation in Localized Small Cell Cancer: A New Approach to Combined Radiotherapy and Chemotherapy. *Proc Am Soc Clin Oncol* 19:383, 1978.
7. Dragon LH, Ettinger DS, Gupta PK, and Lenhard RE, Jr. Sputum Cytologic Diagnosis of Hodgkin's Disease (HD) Involving the Lung. *Proc Am Soc Clin Oncol* 19:383, 1978.
8. Baylin SB, Abeloff MD, Eggleston JC, Weisburger WR, Mendelsohn G, and Ettinger DS. Biochemical Heterogeneity in Small Cell Carcinoma of the Lung - Biological and Clinical Implications. *Proc. World Conf. Lung Cancer*. Hilton Head Island, South Carolina. Abstract #70, May 10-13, 1978.
9. Order SE, Klein JL, Sgagias M, Lichter AS, Ettinger DS, Dillon M, and Rosenshein NB. New Methods Applied to the Analysis and Treatment of Ovarian Cancer. *Int J Rad Oncol Biol Phys* 4(Suppl 2):159, 1978.
10. Abeloff MD, Eggleston JC, Mendelsohn G, Ettinger DS, and Baylin SB. Changes in Morphologic and Biochemical Characteristics of Small Cell Carcinoma of the Lung. *Proc Am Assoc Cancer Res* 20:38, 1979.
11. Abeloff MD, Ettinger DS, Khouri NF. Intensive Induction Therapy for Small Cell Carcinoma of the Lung. *Proc Am Soc Clin Oncol* 20:326, 1979.
12. Order SE, Leibel SA, Klein JL, Sgagias M, Ettinger DS, and Trump DL. Isotopic Immunoglobulin Therapy. A Phase I-II Trial. *Proc Am Soc Clin Oncol* 20:366, 1979.
13. Waalkes TP, Woo KB, Abeloff MD, Ruddon RW, Ettinger DS, and Aldenderfer P. Monitoring Treatment by Sequential CEA Levels for Patients with Small Cell Carcinoma of the Lung. *Proc Am Soc Clin Oncol* 20:418, 1979.
14. Wharam MD, Leibel SA, Order SE, Brereton H, Ettinger DS, and Abeloff MD. The Dose Modifying Effect of Concomitant CMF Adjuvant Therapy and Chest Wall Irradiation. *Proc Am Soc Clin Oncol* 20:367, 1979.
15. Ettinger DS, Rosenshein NB, Parmley TH, and Baylin SB. Elevated Histaminase Activity in Ovarian Carcinoma. *Proc Am Assoc Cancer Res* 20:64, 1979.

16. Ettinger DS, Stanley KE, Nystrom JS, for the Eastern Cooperative Oncology Group. High Dose Methotrexate with Citrovorum Factor Rescue in Inoperable Non-Oat Cell Bronchogenic Carcinoma. *Proc Am Soc Clin Oncol* 20:347, 1979.
17. Leibel SA, Order SE, Wharam MD, Ettinger DS, and Rosenshein NB. Sequential Multimodality Therapy of Ovarian Cancer with New Treatment Techniques. *Proc Am Soc Clin Oncol* 20:379, 1979.
18. Order SE, Leibel SA, Klein JL, Sgagias M, Ettinger DS, Trump DL, and Leichner P. A Phase I-II Study of Radiolabeled Antibody Integrated in Multimodal Treatment of Primary Hepatic Malignancies. *Int J Rad Oncol Biol Phys* 5(Suppl. 2):120, 1979.
19. Pendergrass KB, Abeloff MD, Ettinger DS, Burke PJ, Order SE, and Khouri NF. Intensive Timed Sequential Combination Chemotherapy and Adjunctive Radiotherapy in Extensive Stage Small Cell Carcinoma of the Lung. *Proc Am Soc Clin Oncol* 21:447, 1980.
20. Woo KB, Waalkes TP, Abeloff MD, Ettinger DS, and Gehrke CW. Quantitation of Treatment Response by Urinary Polamines and b-Aminoisobutyric Acid (b-AIBA) in Small Cell Carcinoma of the Lung (SCC). *Proc Am Assoc Cancer Res* 21:170, 1980.
21. Order SE, Klein JL, Ettinger DS, Siegelman S, Alderson P, and Leichner P. Isotopic Immunoglobulin Dosimetry, Toxicity, and Therapeutic Potential. *Proc Am Soc Clin Oncol* 21:395, 1980.
22. Order SE, Wharam MD, Klein J, Crisp R, Alderson P, Siegelman S, Ettinger DS, Strand M, and Leichner P. The Biological Implantation of Cancer by Isotopic Antiferitin Immunoglobulin. *Int J Rad Oncol Biol Phys* 6:1348, 1980.
23. Order SE, Klein JL, Ettinger DS, Wharam MD, Humphrey RL, and Leichner PK. Dose, Specificity and Labeling Ratio in Isotopic Immunoglobulin Therapy. *Proc Am Soc Clin Oncol* 22:414, 1981.
24. Khaneja S, Thant M, and Ettinger DS. Combination Chemotherapy with Cyclophosphamide (C), Adriamycin (A) and Mitomycin C (M) in Advanced Non-Small Cell Bronchogenic Carcinoma (NSBC). *Proc Am Soc Clin Oncol* 22:416, 1981.
25. Diasio RB, Ettinger DS, and Satterwhite BE. Levonantradol, A Synthetic Cannabinoid with Potential Usefulness as an Antiemetic in Chemotherapy- Induced Emesis. *Proc Am Soc Clin Oncol* 22:416, 1981.
26. Pino y Torres J, Rosenshein N, Klein JL, Ettinger DS, Leichner PK, and Order SE. Multimodality Treatment of Stage-III Ovarian Cancer. *Int J Rad Oncol Biol Phys* 7:1268, 1981.

27. Ruckdeschel JC, Mason B, Ettinger D, Creech R, Mehta C, and Stanley D. Chemotherapy of Metastatic Non-Oat Cell Bronchogenic Carcinoma: The Eastern Cooperative Oncology Group. Presented at III World Conf. on Lung Cancer, Tokyo, Japan, May 17-20, 1982.
28. Ruckdeschel JC, Mason B, Ettinger DS, Creech R, Mehta C, and Stanley K. Failure to Define a "Standard" Chemotherapy for Metastatic Non-Small Cell Bronchogenic Carcinoma. *Proc Am Assoc Cancer Res* 23: 144, 1982.
29. Markman M, Berkman A, Griffin C, Ettinger DS, and Abeloff M. Intensive Alternating Non-Cross Resistant Chemotherapy + Radiotherapy for Small Cell Carcinoma (SCC). *Proc Am Assoc Cancer Res* 23:147, 1982.
30. Leichner PK, Siegelman SS, Klein JL, Ettinger DS, Wallace J, and Order SE. Dosimetry of ¹³¹I-Labeled Antiferritin in Hepatoma, Specific Activities in the Tumor and Proportionality of Maximum Tumor Activity to Tumor Volume. *Int J Rad Oncol Biol Phys* 8(Suppl 1): 120, 1982.
31. Order SE, Ettinger DS, Klein J, Leichner P, Leibel S, Wharam MD, Adams J, Kopher K, and Chambers J. Radiolabeled Antibodies in the Treatment of Primary Hepatic Malignancies. *Int J Rad Oncol Biol Phys* 8(Suppl 1):121, 1982.
32. Ettinger DS, Leichner PK, Siegelman SE, Klein JL, Chambers JP, and Order SE. Computed Tomography (CT) Assisted Volumetric Analysis of Primary Liver Tumors as a Measure of Response to Therapy. *Proc Am Soc Clin Oncol* 2:115, 1983.
33. Order SE, Ettinger DS, Leibel SA, Klein JL, and Leichner PK. Cyclic Radiolabeled ¹³¹I Antiferritin in Multimodality Therapy of Hepatocellular Carcinoma. *Proc Am Soc Clin Oncol* 2:119, 1983.
34. Orr DW, Ettinger DS, Rice AP, Colvin OM, Grochow LB, and Donehower RC. Phase I and Pharmacokinetic Study of N-Methylformamide (NMF). *Proc Am Soc Clin Oncol* 2:24, 1983.
35. Lenhard RE, Order SE, Spunberg JJ, Ettinger DS, Asbell SO, and Leibel SA. Radioimmunoglobulins: A New Therapeutic Modality in Hodgkin's Disease. *Proc Am Soc Clin Oncol* 2:211, 1983.
36. Hernandez E, Rosenshein NB, Parmley T, Bhagavan B, Wijnen H, Dillon MB, Ettinger DS, and Munoz L. Tumor Cell Heterogeneity in Epithelial Ovarian Cancer. *Proc Am Soc Clin Oncol* 2:150, 1983.
37. Leichner PK, Siegelman SS, Klein JL, Ettinger DS, Fishman EK, and Order SE. Comparative Tumor Dose with ¹³¹I Labeled Antiferritin, Anti-AFP and Anti-CEA in Primary Liver Cancers. *Int J Rad Oncol Biol Phys* 9(Suppl):124, 1983.

38. Ettinger DS, Sheidler V, Markman M, Quaskey SA, and Mellits ED. Antiemetic Efficacy of Dexamethasone (DEX): Randomized Double-Blind Crossover Study with Prochlorperazine (PCP). *Proc Am Soc Clin Oncol* 3:90, 1984.
39. Brown T, Ettinger DS, Rice A, Poremski C, Donehower R. A Phase I Clinical Trial of Spirohydantoin Mustard (SHM). *Proc Am Soc Clin Oncol* 3:33, 1984.
40. Order SE, Klein J, Leichner P, Self S, Leibel S, Ettinger D. I¹³¹ Radiolabeled Antibody (Antiferritin) in the Treatment of Hepatoma - An Update. *Proc Am Soc Clin Oncol* 3:138, 1984.
41. Bunting N, Bonomi P, O'Reilly W, Vogl S, Creech R, Ruckdeschel J, Stolbach L, Ettinger DS. Prognostic Factors in Patients with Small Cell Bronchogenic Carcinoma (SCBC) Treated on an ECOG Phase II Trial. *Proc Am Soc Clin Oncol* 3:228, 1984.
42. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl SE, and Joss RA. Chemotherapy of Metastatic Non-Small Cell Bronchogenic Carcinoma (NSCBC): A Randomized Comparison of the Four Most Active Regimens. *Proc Am Assoc Cancer Res* 25:171, 1984.
43. Ruckdeschel JC, Finkelstein DM, Creech RH, and Ettinger DS. Chemotherapy of Metastatic Non-Small Cell Bronchogenic Carcinoma. *Clin Res* 32(No. 2):421A, 1984.
44. Donehower RC, Graham ML, Thompson GE, Dole GB, and Ettinger DS. Phase I and Pharmacokinetic Study of Trimetrexate (TMTX) in Patients with Advanced Cancer. *Proc Ann Soc Clin Oncol* 4:32, 1985.
45. Longnecker S, Donehower R, Grochow L, Cates A, Rice A, Colvin M, Ettinger, D., and Green, L. Phase I and Pharmacokinetic Study of Taxol in Patients with Advanced Cancer. *Proc Am Soc Clin Oncol* 4:32, 1985.
46. Brown TD, Donehower RC, Grochow LB, Ettinger DS, Rice AP, and Waalkes TP. A Phase I Study of Menogaril (MEN) in Patients with Advanced Cancer. *Proc Am Soc Clin Oncol* 4:32, 1985.
47. Grochow LB, Donehower RC, Ettinger DS, Cates AE, and Rice A. Pharmacokinetics of Menogaril (MEN). *Proc Am Soc Clin Oncol* 4:32, 1985.
48. Hornedo-Muguiro J, So M, Spaulding MB, Van Echo DA, Donehower R, Ettinger DS, and Aisner J. Phase II Trial of Carboplatin (CBDCA) in Aerodigestive Malignancies. *Proc Am Soc Clin Oncol* 4:136, 1985.
49. Ettinger DS, Baker RR, Eggleston JC, Abeloff MD, Ruckdeschel JC, McKneally MF, Woll J, and Edelstein D. Prospective Evaluation of the Role of Surgery in Limited Disease (LD) Small Cell Lung Cancer (SCLC). An ECOG Study. *Proc Am Soc Clin Oncol* 4:180, 1985.

50. Olver IN, Donehower RC, Van Echo DA, Ettinger DS, and Aisner J. Phase II Trial of Carboplatin (CBDCA) in Non-Small Cell Lung Cancer (NSCLC). *Proc Am Soc Clin Oncol* 4:182, 1985.
51. Bonomi P, Pazdur R, Stolbach L, Mason B, and Ettinger DS. A Phase II Trial of Mitomycin, Vindesine, and Hexamethylmelamine in Non-Small Cell Bronchogenic Carcinoma (NSCBC) -- An ECOG Pilot Study. *Proc Am Soc Clin Oncol* 4:183, 1985.
52. Wagner H, Ruckdeschel J, Bonomi P, Danjoux C, Richter M, and Ettinger DS. Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) with Mitomycin C, Vinblastine and cis-DDP (MVP) Followed by Radiation Therapy (RT): An ECOG Pilot Study. *Proc Am Soc Clin Oncol* 4:183, 1985.
53. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Mason BA, Vogl, S.E., and Joss, R.A. Predictors of Improved Response and Survival in Metastatic Non-Small Cell Bronchogenic Carcinoma (NSCBC). *Proc Am Soc Clin Oncol* 4:187, 1985.
54. Green S, Peroutka S, Sheidler V, Redden T, Snyder S, and Ettinger DS. A Neuropharmacologic Approach to Antiemetic Therapy: A Double-Blind, Randomized Trial of Combination Antiemetics. *Proc Am Soc Clin Oncol* 4:260, 1985.
55. Ruckdeschel JC, Finkelstein DM, and Ettinger DS. Chemotherapy of Metastatic Non-Small Cell Lung Cancer (NSCLC): The Eastern Cooperative Group Experience. IV World conference on Lung Cancer, Toronto, Canada, August 25-30, 1985.
56. Order SE, Klein JL, Leichner PK, and Ettinger DS. The Treatment of Hepatocellular Cancer: A Clinical Model for Radiolabeled Antibody Therapy. *Cancer Drug Deliv* 2:235, 1985.
57. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, and Aisner S. A Randomized Comparison of Conventional Chemotherapy with Immediate Alternation of Non-Cross Resistant Chemotherapy in Extensive Disease (ED) Small Cell Lung Cancer (SCLC). *Proc Am Soc Clin Oncol* 5:170, 1986.
58. Rowinsky EK, Ettinger DS, Donehower RC, Grochow LB, Brundrett RB, Cates AE, and Rice AP. Phase I and Pharmacokinetic Study of Hexamethylene Bisacetamide (HMBA). *Proc Am Soc Clin Oncol* 5:31, 1986.
59. Ettinger DS, Finkelstein DM, Harper GR, Ruckdeschel JC, Chang AYC, Camacho FJ, Marsh JC, Silber R, and Wolter, J.M. Phase II Study of Mitoxantrone, Aclarubicin, and Diaziquone in the Treatment of Non-Small Cell Lung Carcinoma: An Eastern Cooperative Oncology Group Study. *Toxicology Abstracts* 9:30, 1986.

60. McGuire WP, Rowinsky EK, Ettinger DS, Grochow LB, Luk GD, and Donehower RC. Prolonged Infusion of Hexamethylene Bisacetamide (HMBA) Phase I and Pharmacologic Study. *Proc Am Assoc Cancer Res.* 28:193, 1987.
61. Hantel A, Rowinsky EK, Ettinger DS, Grochow LB, McGuire WP, and Donehower RC. Clinical and Pharmacologic Reappraisal of Dichloromethotrexate (DCMTX). *Proc. Am. Assoc. Cancer Res.* 28:201, 1987.
62. Kennedy P, Eisenberger M, Silva H, Krasnow S, Perry D, Ettinger D, Ellenberg S. Toxicity of Carboplatin (CBDCA) in Combination with Methotrexate (MTX) in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN). *Proc Am Soc Clin Oncol* 6:136, 1987.
63. Ettinger DS, Mehta CR, Abeloff MD, Ruckdeschel JC, Aisner S. Maintenance Chemotherapy Versus No Maintenance Chemotherapy in Complete Responders Following Induction Chemotherapy in Extensive Disease (ED) Small Cell Lung Cancer (SCLC). *Proc Am Soc Clin Oncol* 6:175, 1987.
64. Beveridge R, Chan D, Ettinger DS, Rock R, Bruzek D, Damron D, Bray K, and Gaur P. A New Marker for Breast Cancer - CA 549. Second Conference on Immunity to Cancer. Williamsburg, Virginia, November 9-11, 1987.
65. Rowinsky EK, Burke PJ, Karp JE, Ettinger DS, Tucker RW, and Donehower RC. Phase I Study of Taxol in Refractory Adult Acute Leukemia. *Proc Am Assoc Cancer Res* 29:215, 1988.
66. Donehower R, Vito B, Noe D, Rowinsky E, McGuire W, Grochow L, Abeloff M, Ettinger DS, Hantel A, Shen H, Lee F, and Demos C. Phase I and Pharmacokinetic Study of Brequinar (BREQ, DuP-785). *Proc Am Soc Clin Oncol* 7:65, 1988.
67. Hantel A, Noe DA, Rowinsky EK, Vito BL, Hurowitz L, McGuire WP, Ettinger DS, and Donehower, RC. A Phase I and Pharmacokinetic Study of Oxantrazole (OAZ). *Proc Am Soc Clin Oncol* 7:66, 1988.
68. Rowinsky EK, Donehower RC, Rosenshein NB, Ettinger DS, and McGuire WP. Phase II Study of Taxol in Advanced Ovarian Epithelial Malignancies. *Proc Am Soc Clin Oncol* 7:136, 1988.
69. Bonomi P, Aisner SC, Ettinger DS, and Finkelstein D. Phase II Trial of Cisplatin in Recurrent or Metastatic Malignant Thymoma: An ECOG Trial. *Proc Am Soc Clin Oncol* 7:221, 1988.
70. Beveridge RA, Chan DW, Ettinger DS, Rock RC, Bruzek DJ, Damron DJ, Bray KR, and Gaur PK. A New Marker for Breast Cancer (Br Ca) - CA 549. *Proc Am Soc Clin Oncol* 7:23, 1988.

71. Aisner SC, Ettinger D, Finkelstein D, Ruckdeschel JD, Mehta C, Abeloff M, and Eggleston J. The Clinical Significance of Variant Morphology (Small Cell/Large Cell) Small Cell Carcinoma of the Lung (SCCL). *Proc Am Soc Clin Oncol* 7:195, 1988.
72. Aisner SC, Ettinger DS, Finkelstein D, Ruckdeschel JD, Mehta C, Abeloff M, Eggleston J. The Clinical Significance of Variant Morphology Small Cell Lung Carcinoma (SCCL) Using the 1984 IASLC Classification System. *Lung Cancer* 4(Suppl):A41, 1988.
73. Epstein B, Ettinger DS, Leichner P, Order SE. Multimodality Cisplatin Treatment in Nonresectable AFP Positive Hepatoma: Preliminary Results. *Int J Rad Oncol Bio Phys* 17:185, 1989.
74. Rowinsky EK, Ettinger DS, Noe DA, Vito BL, Fishman EK, Hantel A, Grochow LB, and Donehower RC. Phase I and Pharmacologic Study of 4-Ipomeanol in Patients with Lung Cancer. *Proc Am Soc. Clin Oncol* 8:72, 1989.
75. Order S, Pajak T, Klein J, Leichner P, Ettinger DS, Asbell S, and Leibel S. A Randomized Prospective Trial in Nonresectable Hepatoma Comparing Adriamycin and 5-Fluorouracil \pm 131 I Antiferritin: An RTOG Study. *Proc Am Soc Clin Oncol* 8:99, 1989.
76. Marin L, Calkins A, Vriesendorp H, Ettinger D, and Order S. Phase I-II Treatment Using Simultaneous Adriamycin and Radiation for Rare Malignant Tumors. *Proc Am Soc Clin Oncol* 8:291, 1989.
77. Anderson PN, Cowan DH, Cady B, and Ettinger DS. Use of Medical Quality Management Concepts in Oncology Clinical Practice and Cancer Control. *Proc Am Soc Clin Oncol* 9:61, 1990.
78. Miller CB, Platanius LC, Ratain MJ, Hart RD, Ettinger DS, Mills SR, and Jones RJ. A Phase I/II Trial of Erythropoietin (EPO) in the Treatment of Chemotherapy-Induced Anemia in Patients With Cancer. *Proc Am Soc Clin Oncol* 9:194, 1990.
79. Ettinger DS, Finkelstein DM, Abeloff MD, and Bonomi PD. Justification for Evaluating New Anticancer Drugs in Selected Untreated Patients With a Chemotherapy-Sensitive Advanced Cancer: An ECOG Randomized Study. *Proc Am Soc Clin Oncol* 9:224, 1990.
80. Simons JW, Rowinsky EK, McGuire WP, Forastiere AA, Nelson WG., Ettinger DS, Grochow LB, Clarke BV, Lubejko BG, Duerr MT, Bergers JK, Marshall FF, and Donehower RC. Phase I Study of Overlapping Continuous Infusion VP-16 and Recombinant Human Tumor Necrosis Factor in Advanced Cancer. *Proc Am Soc Clin Oncol* 9:200, 1990.
81. Rowinsky E, Gilbert M, McGuire W, Clarke B, Ettinger DS, Lubejko B, Forastiere A, Grochow L, Hendricks C, Noe D, and Donehower R. Sequences of Taxol + Cisplatin: Phase I/Pharmacologic Study. *Proc Am Soc Clin Oncol* 9:75, 1990.

82. Hendricks CB, Grochow LB, Rowinsky EK, Ettinger DS, McGuire WP, Forastiere AA, Clarke BV, Lubejko BG, Duerr MT, Noe DA, Baba C, Hurowitz L, and Donehower RC. Phase I and Pharmacologic Study of Hepsulfam. *Proc Am Soc Clin Oncol* 9:75, 1990.
83. Rowinsky E, Grochow L, Hendricks C, Satorius S, Ettinger D, McGuire W, Forastiere A, Hurowitz L, Easter V, and Donehower R. Phase I and pharmacologic study of topotecan (SK-F 104864): a novel Topoisomerase I inhibitor. *Proc Am Soc Clin Oncol* 10:93, 1991.
84. Donehower R, Noe D, Forastiere A, Grochow L, Ettinger D, Rowinsky E, McGuire W, Hendricks C, King P, Lisi T, and Winslow D. Phase I bioavailability (BIO) and pharmacokinetic (PK) study of oral brequinar (BREQ) in patients with advanced cancer. *Proc Am Soc Clin Oncol* 10:95, 1991.
85. Grossman SA, Ruckdeschel JC, Moynihan T, Finkelstein D, Ettinger D, Mohoney E, and Trump D. Randomized prospective comparison of intraventricular (IT) methotrexate (MTX) and Thiotepea (T^T) for neoplastic meningitis (NM). *Proc Am Soc Clin Oncol* 10:127, 1991.
86. Ettinger DS, Bitran JD, Comis RL, Langer CJ, Harwood KV, Harris CL, Keller JH, and Losada M. Etoposide and Mitomycin in Treatment of Non-Small-Cell Lung Cancer, Phase I-II Evaluation. *Respir Dis Dig* 7:17, 1992.
87. Rowinsky E, Grochow L, Ettinger D, Hendricks C, Lubejko B, Sartorius S, Hurowitz L, McGuire W, Rock M, and Donehower R. Phase I and pharmacologic study of CPT-11, a semisynthetic topoisomerase I - targeting agent, on a single dose schedule. *Proc Am Soc Clin Oncol* 11:115, 1992.
88. Rowinsky EK, Lubejko BG, Noe DA, Ettinger DS, Christian MC, Hendricks CB, Baba CK, Fishman EK, Sartorius SE, and Donehower RC. Phase I and pharmacologic study of 4-Ipomeanol (IPO), a lung toxin, on a single dose schedule: Hepatotoxicity is dose-limiting in humans. *Proc Am Soc Clin Oncol* 11:115, 1992.
89. Forastiere AA, Rowinsky E, Chandry V, Sartorius S, Lubejko B, Ettinger D, Grochow L, and Donehower R. Phase I trial of Taxol (T) and Cisplatin (C) + G-CSF in solid tumors. *Proc Am Soc Clin Oncol* 11:117, 1992.
90. Ettinger D, Finkelstein D, Ritch P, Bonomi P, and Blum R. Randomized Trial of Single agents vs. combination chemotherapy in extensive stage small cell lung cancer (SCLC). *Proc Am Soc Clin Oncol* 11:295, 1992.
91. Borkowski J, Donehower R, Ettinger D, and Grochow L. Is the Clearance Rate (CL) of Anticancer Drugs Altered in Aging Patients? A Review of Data from Phase I Trials. *Proc Am Soc Clin Oncol* 12:139, 1993.

92. Donehower R, Grove W, Whitfield L, Grochow L, Ettinger D, Forastiere A, McGuire W, Kowal C, and Rowinsky E. Successful Use of Pharmacologically Guided Dose Escalation (PGDE) in a Phase I Trial of CI-958. *Proc Am Soc Clin Oncol* 12:139, 1993.
93. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RLS, Coughlin C, Scarantino C, Rotman M, and Emami B. Concurrent Hyperfractionated Irradiation and Chemotherapy for Non-Small Cell Lung Cancer. Preliminary Report of a Phase I/II Radiation Therapy Oncology Group (RTOG) Trial. *Proc Am Soc Clin Oncol* 12:327, 1993.
94. Ettinger DS, Finkelstein DM, Sarma R, and Johnson DH. Phase II Study of Taxol in Patients (PTS) with Extensive-Stage Small Cell Lung Cancer (SCLC). *Proc Am Soc Clin Oncol* 12:329, 1993.
95. Rowinsky E, Noe D, Grochow L, Chen T, Slichenmyer W, Lubejko B, Ettinger D, Sartorius S, Bowling K, Kaufmann S and Donehower R. Phase I and Pharmacokinetic (PK) Studies of Pyrazoloacridine (PA) on Single 1-3 hr Infusion and Daily x 5 Day Schedules. *Proc Am Soc Clin Oncol* 13:141, 1994.
96. Rowinsky E, Grochow L, Kaufmann S, Bowling K, Sartorius S, Chen T, Lubejko B, Ettinger D, Peereboom D and Donehower R. Sequence-Dependent Effects of Topotecan (T) and Cisplatin (C) in a Phase I and Pharmacokinetic (PK) Study. *Proc Am Soc Clin Oncol* 13:142, 1994.
97. Tucker MA, Murray N, Shaw EG, Huber MH, Ettinger DS, Mabry M, Feld R, Shepherd FA, Grant SC, Johnson DH, Aisner J, Johnson BE for the Lung Cancer Working Cadre. Risk of Second Cancer (SC) in 2 Year Survivors of Small Cell Lung Cancer (SCLC). *Proc Am Soc Clin Oncol* 13:331, 1994.
98. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JC, Bonomi PD and Johnson DH. A Phase II Study of Ifosfamide, Carboplatin, and Oral Etoposide (ICE) Chemotherapy for Extensive-Disease (ED) Small Cell Lung Cancer (SCLC): An Eastern Cooperative Oncology Group Pilot Study. *Proc Am Soc Clin Oncol* 13:357, 1994.
99. Johnson BE, Murray N, Shaw EG, Huber MH, Ettinger DS, Mabry M, Feld R, Shepard FA, Grant SC, Johnson DH, Aisner J, Tucker MA for the Lung Cancer Working Cadre. Risk of Second Cancers (SC) in Long-Term Survivors of Small Cell Lung Cancer (SCLC). *Lung Cancer* 11(Suppl 1):58, 1994.
100. Byhardt RW, Scott CB, Ettinger DS, Curran WJ, Doggett RLS, Coughlin C, Scarantino C, Rotman M and Emami B. Concurrent Hyperfractionated Irradiation and Chemotherapy for Non-Small Cell Lung Cancer. Preliminary Report of a Phase I/II Radiation Therapy Oncology Group (RTOG) Trial. *Lung Cancer* 11(Suppl 1):188, 1994.
101. Ettinger DS. Paclitaxel in the Treatment of Lung Cancer. *Lung Cancer* 11(Suppl 2):76, 1994.

102. Ettinger DS. New Drugs for Treating Small Cell Lung Cancer. *Lung Cancer* 11(Suppl 2):236, 1994.
103. Ettinger DS. The Place of Ifosfamide in Chemotherapy of Small Cell Lung Cancer (SCLC): The ECOG Experience and a Selected Literature Update. *Lung Cancer* 11(Suppl 2):76, 1994.
104. Rowinsky EK, Sartorius SE, Bowling MK, Wagner JW and Ettinger DS. Paclitaxel on a 3-Hour Schedule and Carboplatin in Non-Small Cell Lung Cancer: Use of Maximally Tolerated and Clinically Relevant Single Agent Doses in Combination is Feasible. *Proc Am Soc Clin Oncol* 14:354, 1995.
105. Kim K, Ettinger D, Bonomi P, Johnson D for the Eastern Cooperative Oncology Group. Treatment Effects on Survival Within Gender and Race Subgroups in Lung Cancer. ECOG's Experience. *Proc Am Soc Clin Oncol* 14:360, 1995.
106. Levitan N, McKenney J, Tahsildar H and Ettinger D. Results of a Phase I Dose Escalation Trial of Paclitaxel, Etoposide and Cisplatin Followed by Filgrastim in the Treatment of Patients with Extensive Stage Small Cell Lung Cancer. *Proc Am Soc Clin Oncol* 14:379, 1995.
107. Komaki R, Scott C, Ettinger D, Lee JS, Murphy W, Curran W, Evans R, Rubin P, Byhardt R. Randomized Phase II Study of Chemotherapy/Radiation Therapy Combinations for Favorable Patients with Locally Advanced Inoperable Non-Small Cell Lung Cancer: Radiation Therapy Oncology Group 92-04. *Proc Am Soc Clin Oncol* 15:514, 1996.
108. Belani CP, Bonomi P, Dobbs T, DeVore K, Ettinger D, Jett J, Kozak C, Cohen L, Capazzoli MJ, Johnson D. Multicenter Phase II Trial of Docetaxel and Cisplatin Combination in Patients with Non-Small Cell Lung Cancer. *Proc Am Soc Clin Oncol* 16:462, 1997.
109. Ettinger DS. Carboplatin in the Treatment of Small Cell Lung Cancer (SCLC). *Lung Cancer* 18 (Suppl 2):132, 1997.
110. Ettinger DS, Bowling K, Hoker B, Chen TL, Zabelina Y, Casero RA. Phase I Study of N¹,N¹¹-Diethylnorspermine (DENSPM) in Patients with Non-Small Cell Lung Cancer (NSCLC). *Proc Am Soc Clin Oncol* 17:190, 1998.
111. Aisner SC, Turrisi A, Kim KM, Sause WT, Livingston RB, Einhorn L, Wagner H, Ettinger D, Komaki R, Blum R, Johnson DH. Incidence and Clinical Significance of Variant Morphology (Small Cell/Large Cell Subtype) in Limited Stage Small Cell Lung Cancer (SCLC). A Prospective Analysis of an Intergroup ECOG, RTOG and SWOG Study. *Proc Am Soc Clin Oncol* 17:458, 1998.

112. Jiroutek M, Johnson D, Blum R, Bonomi P, Chan A, Ettinger D, Ruckdeschel, Schiller J, Sandler A. Prognostic Factors in Advanced Non-Small Cell Lung Cancer (NSCLC): Analysis of Eastern Cooperative Group (ECOG) Trials from 1981-1992. *Proc Am Soc Clin Oncol* 17:461, 1998.
113. Lee JS, Schott CB, Komaki R, Ettinger D, Sause WT. Effects of the Number of Patients Treated Per Institution on the Outcome of Therapy in Patients with Locally-Advanced Inoperable Non-Small Cell Lung Cancer: RTOG 91-06 and RTOG 92-04 Experience. *Proc Am Soc Clin Oncol* 18:459, 1999.
114. Ettinger DS, Seiferheld WF, Abrams RA, Fontanesi J, Machtay M, Duncan PJ, Curran WJ, Byhardt RW. Cisplatin (P), Etoposide (E), Paclitaxel (T) and Concurrent Hyperfractionated Thoracic Radiotherapy (TRT) for Patients (Pts) with Limited Disease (LD) Small Cell Lung Cancer (SCLC): Preliminary Results of RTOG 96-09. *Proc Am Soc Clin Oncol* 19:490, 2000.
115. Ettinger DS, Bunn PA, LeChevalier T. Gemcitabine + ALIMTA in Advanced Non-Small Cell Lung Cancer (NSCLC): Why this regimen? *Lung Cancer* 29(Suppl 2):58, 2000.
116. Komaki R, Seiferheld W, Ettinger D, Lee JS, Movsas B, Sause W. Randomized Chemoradiation for Patients with Locally Advanced Inoperable Non-Small Cell Lung Cancer (NSCLC): Long-Term Follow-Up of RTOG 92-04. *Lung Cancer* 29(Suppl 1):93, 2000.
117. Ettinger DS. New Agents for Previously Untreated Small Cell Lung Cancer. *Lung Cancer* 29(Suppl 2):23, 2000.
118. Sause WT, Scott C, Komaki R, Byhardt R, Lee JS, Curran W, Movsas B, Ettinger DS. Combined Chemotherapy Radiation Therapy Treatment in Unresectable Non-Small Cell Lung Cancer - Radiation Therapy Oncology Group Experience. *Lung Cancer* 29(Suppl 2):58, 2000.
119. Ettinger DS. ALIMTA (MTA) Overview-Preclinical Data, Phase I Studies, Single Agent Activity in NSCLC. *Lung Cancer* 29(Suppl 2):69, 2000.
120. Kraybill WG, Spiro I, Harris J, Ettinger D, Trotti D, Lucas D, Blum R, Eisenberg B. Radiation Therapy Oncology Group (RTOG) 95-14: A Phase II Study of Neoadjuvant Chemotherapy (CT) and Radiation Therapy (RT) in High Risk (HR), High Grade, Soft Tissue Sarcomas (STS) of the Extremities and Body Wall: A Preliminary Report. *Proc Am Soc Clin Oncol* 20:348, 2001.
121. Ettinger D, Hsu C, Bradley J, Pilepich M, Machtay M, Komaki R, Atkins J, Curran W, Graham M. Phase II Study of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II and IIIA Non-Small Cell Lung Cancer. *Int J Radiat Oncol Biol Phys* 51(Suppl 1):23, 2001.

122. Pili R, Langston-Webster B, Morris CR, Rasmussen C, Ettinger DS, Brahmer JR, Yung RC, Heath E. Antitumor Effect of IM862 Aerosol Treatment in Lung Tumor Models. *Proc Am Soc Clin Oncol* 21:116, 2002.
123. Loehrer PJ, Wang W, Ettinger DS, Aisner SC, Johnson DH. Phase II Study of Octreotide Treatment in Advanced or Recurrent Thymic Malignancies. An Eastern Cooperative Oncology Group Study. *Proc Am Soc Clin Oncol* 21:295, 2002.
124. Ettinger DS, Monnerat C, Kelly K, Novello S, Brahmer JR, Readet DD, Rusthoven J, Bunn PA, LeChevalier T. Phase II Trial of Pemetrexed + Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer: Importance of Survival Over Response. *Proc Am Soc Clin Oncol* 21:311, 2002.
125. Komaki R, Swann S, Ettinger D, Glisson B, Sandler A, Movsas B, Byhardt R. Phase I Dose-Escalation Study of Thoracic Irradiation with Concurrent Chemotherapy for Patients with Limited Small Cell Lung Cancer (LSCLC). Radiation Therapy Oncology Group (RTOG) Protocol 9712. *Proc Am Soc Clin Oncol* 22:631, 2003.
126. Kraybill WG, Harris JH, Spiro I, Ettinger D, Trotti A, Lucas D, Blum R, Eisenberg B. Radiation Therapy Oncology Group (RTOG) 95-14: A Phase II Study of Neoadjuvant Chemotherapy (CT) and Radiation Therapy (RT) in the Management of High Risk (HR), High Grade, Soft Tissue Sarcomas (STS) of the Extremities and Body Wall. *Proc Am Soc Clin Oncol* 22:815, 2003.
127. Movsas B, Moughan J, Komaki R, Choy H, Byhardt R, Langer C, Goldberg M, Graham M, Ettinger D, Johnstone D, Owen J. Radiotherapy Patterns of Care Study in Lung Cancer. *Lung Cancer* 41(Suppl 2):530, 2003.
128. Komaki R, Swann S, Ettinger D, Glisson B, Sandler A, Movsas B, Byhardt R. Phase I Dose Escalation Study of Thoracic Irradiation with Concurrent Chemotherapy for Patients with Limited Small Cell Lung Cancer (LSCLC). Radiation Therapy Oncology Group (RTOG) Protocol 9712. *Lung Cancer* 41(Suppl 2):S104, 2003.
129. Choy H, Swann S, Sandler A, Whipple G, Demas WF, Ettinger D. A Phase I Trial of Gemcitabine, Carboplatin or Gemcitabine, Paclitaxel and Concurrent Radiation Therapy Followed by Consolidative Gemcitabine and Carboplatin for Inoperable Stage III Non-Small Cell Lung Cancer: An RTOG Study. *Lung Cancer* 41(Suppl 2):S133, 2003.
130. Ettinger DS. Chemotherapy for Advanced NSCLC. *Japanese J Lung Cancer* 43:424, 2003.
131. Aisner SC, Hameed MR, Wang W, Schiller JH, Johnson DH, Ettinger DS, Loehrer PJ. EGFR and C-Kit Immunostaining in Advanced or Recurrent Thymic Epithelial Neoplasms Staged According to the WHO: An Eastern Cooperative Oncology Group Study, *Proc Am Soc Clin Oncol* 23:865, 2003.

132. Choy H, Swann S, Walter C, Whipple G, Demas W, Ettinger D. A phase I trial of gemcitabine, carboplatin, or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: An RTOG study. *Proc Am Soc Clin Oncol* 23:165, 2005 (Abstr 7103)
133. Yung R, Gramatikova A, Brock M, Brahmer J, Ettinger D, Friedman K, Jacene H, Colvin L, Lang P, Yang S. How dedicated Positron Emission Tomography – CT (PET-CT) affects the diagnostic and therapeutic approaches to patients managed by a multimodality thoracic oncology group. *Lung Cancer* 49(Suppl 2):S218, 2005 (Abstr P-391).
134. Swann S, Choy H, Walter C, Whipple G, Remas W, Ettinger D. A phase I trial of gemcitabine, carboplatin, or gemcitabine, paclitaxel and concurrent radiation therapy followed by consolidative gemcitabine and carboplatin for inoperable stage III non-small cell lung cancer: An RTOG study. *Lung Cancer* 49(Suppl 2):S270, 2005 (Abstr P-578).